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SUMMARY 
 
Protein tyrosine phosphorylation is an important signal transduction mechanism, which results in several 
cellular responses including proliferation, survival, differentiation, adhesion and migration. This process of 
protein tyrosine phosphorylation is a reversible posttranslational modification regulated by protein tyrosine 
kinases (PTKs) and protein tyrosine phosphatases (PTPs). Disruption of this tightly regulated process of 
protein tyrosine phosphorylation contributes to the uncontrolled growth of cells and the development of 
tumors. 
 
In the first part of this manuscript, a screening system was developed to select functional shRNAs or siRNAs 
using the transforming capacity of a truncated form of the PDGFRα (tPDGFRα) receptor tyrosine kinase in 
the leukemic Ba/F3 cell line. In this screen effective shRNAs and siRNAs were identified targeting the Pten 
and Cdkn2A genes, which when cloned on the same transcript as the oncogenic PDGFRα resulted in a 
degradation of this transcript. This resultant loss of tPDGFRα blocked the proliferation of the Ba/F3 cells, 
which is a quantifiable and simple read-out for the effectiveness of each shRNA and siRNA. Additional 
advantages of this screening system are the independency of the obtained transduction efficiencies and the 
exclusion of toxic effects after the addition of the growth factor IL-3. 
 
In the second part of the manuscript, we studied the role of PTPRD as a candidate tumor suppressor in 
acute lymphoblastic leukemia (ALL). We observed a high frequency of heterozygous deletions of PTPRD in 
the ALL samples, but found no correlation between the expression level and the copy number. This 
questions the role of PTPRD as a tumor suppressor in ALL. Indeed, often deletions across PTPRD locus 
also cover the region encoding the CDKN2A gene, a well-known tumor suppressor gene and may explain 
this current discrepancy. However, a role for PTPRD in hematopoiesis could not be completely discounted 
because of a high expression in undifferentiated hematopoietic cells and the spleen defects observed in the 
Ptprd knockout mice. Further we confirmed the STAT1 and STAT3 proteins as downstream signaling 
proteins of PTPRD in 293T cells. To further determine whether PTPRD is a tumor suppressor, its role in 
melanoma was further studied as previously had been shown that PTPRD is mutated in 12% of the 
melanoma cases. However, the expression levels of PTPRD were found to be low in melanoma samples and 
in melanocytes and did not correlate with the copy number. Moreover, the described mutations could more 
likely be passenger mutations as they are found across the entire gene in introns next to the exons further 
questioning its ascribed role as a tumor suppressor. 
 
In the last part, we used phospho-proteomics to identify other signaling pathways controlled by PTPN2 next 
to the JAK/STAT pathway in T-ALL. Of the candidate proteins, the tyrosine kinase PTK2B was shown to be a 
bona fide downstream signaling protein of PTPN2 and was rapidly activated after IL-2 and IL-7 cytokine 
stimulation in leukemic cells. The PTK2B activation was found to depend on the SRC kinases and to be 
negatively regulated by PTPN2. Inactivation of PTK2B by siRNA-mediated knockdown or by SRC inhibitors 
had no effect on cell proliferation or migration. 
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SAMENVATTING 
 
Proteïnen tyrosine fosforylatie is een belangrijk mechanisme van signaaltransductie, die verschillende 
cellulaire functies zoals proliferatie, overleving, differentiatie, adhesie en migratie controleert. Dit proces van 
proteïnen tyrosine fosforylatie is een omkeerbare posttranslationele modificatie die gereguleerd wordt door 
proteïnen tyrosine kinasen (PTKs) en proteïnen tyrosine fosfatasen (PTPs). Verstoring van dit nauw 
gereguleerd proces draagt bij tot de ongecontroleerde groei van cellen en de ontwikkeling van tumoren. 
 
In het eerste deel van dit manuscript beschrijf ik de ontwikkeling van een screeningssysteem voor de selectie 
van functionele shRNA’s en siRNA’s door gebruik te maken van de transformerende capaciteit van een 
verkorte vorm van de PDGFRα receptor tyrosine kinase in de leukemie cellijn Ba/F3. Deze screen 
identificeerde werkzame shRNA’s en siRNA’s gericht tegen de Pten en Cdkn2a genen, welke wanneer 
gekloneerd op hetzelfde transcript als de oncogene PDGFRα zorgden voor de degradatie van dit transcript. 
Dit verlies van PDGFRα verhinderde de proliferatie van de Ba/F3 cellen, wat een kwantitatieve en 
gemakkelijke read-out is voor de selectie van werkzame shRNA’s en siRNA’s. Bijkomende voordelen van dit 
screeningssysteem zijn de onafhankelijkheid van de verkregen transductie efficiëntie en de mogelijkheid tot 
uitsluiten van toxische effecten na toevoeging van de IL-3 groeifactor. 
 
In het tweede deel van dit manuscript bestuderen we de rol van PTPRD als een mogelijke tumorsuppressor 
in ALL. We observeerden een hoog aantal heterozygote deleties van PTPRD in ALL stalen, maar vonden 
geen correlatie tussen de gen expressie en het aantal kopijen. Dit stelde de rol van PTPRD als 
tumorsuppressor in vraag. Vaak omvatten de PTPRD deleties ook het CDKN2A locus, een welgekende 
tumorsuppressor, wat een verklaring kan zijn voor de wanverhouding tussen de expressie en het aantal 
kopijen. Nochtans kan de rol van PTPRD in de hematopoëse niet volledig worden uitgesloten, gezien de 
hoge expressie van PTPRD in ongedifferentieerde hematopoëtische cellen en gezien de vastgestelde 
defecten in de milt in de Ptprd knockout muizen. Verder bevestigden we STAT1 en STAT3 als neerwaarts 
gelegen signaalproteïnen van PTPRD in 293T cellen. Een mogelijke rol als tumorsuppressor van PTPRD 
werd verder bestudeerd in melanoma, aangezien eerder werd gerapporteerd dat PTPRD in 12% van de 
melanoma stalen gemuteerd is. De expressie niveau’s van PTPRD waren echter zeer laag in melanoma 
stalen en in melanocyten en correleerden niet met het aantal kopijen. Daarenboven leken de beschreven 
mutaties eerder “passenger” mutaties te zijn door hun verspreide ligging over gans het gen in zowel intronen 
als exonen, wat de beschreven rol van PTPRD als tumorsuppressor verder in vraag stelt. 
 
In het laatste deel gebruikten we phospho-proteomics om andere signaalwegen dan JAK/STAT te 
identificeren die door PTPN2 gereguleerd worden. Van de kandidaat proteïnen leek PTK2B een bonafide 
neerwaarts gelegen signaalproteïne te zijn van PTPN2, die snel geactiveerd werd na IL-2 en IL-7 cytokine 
stimulatie in leukemie cellen. Activatie van PTK2B bleek afhankelijk te zijn van de SRC kinasen en werd 
negatief gereguleerd door PTPN2. Inactivatie van PTK2B door siRNA-gemedieerde knockdown of door SRC 
inhibitors had echter geen effect of celgroei of -migratie. 
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CHAPTER I - INTRODUCTION 
 
1 Cancer 
 
The Belgian Cancer Register noted in 2011 a cancer incidence rate for females of 566,4/100000 
persons/year and for males of 697,4/100000 persons/year. Furthermore, by aged 75, 1 in 3 men and 1 in 4 
women will develop cancer. The current therapy for most cancer types is still chemotherapy, which causes 
severe side effects. In order to find new and more targeted therapies, it is essential to understand the 
multistep process of the development of cancer and its underlying molecular basis. 
 
Cancer can arise in any tissue in the body and occurs when an otherwise normal cell acquires six core 
biological hallmarks to turn it into a tumor cell. These six core hallmarks of cancer were first described by 
Hanahan et al.1 and include the ability of tumor cells to: 1) Sustain continuous proliferation through 
constitutive activation of proliferative signaling pathways or disruption of negative feedback mechanism of 
cell proliferation, 2) evade growth suppression through the inactivation of tumor suppressor genes, which 
normally turn-off proliferation signaling and control the cell cycle progression, 3) resist cell death or 
apoptosis by the loss of pro-apoptotic factors and the upregulation of anti-apoptotic factors, 4) enable 
replicative immortality through the extension of the telomeric DNA at the ends of the chromosome by the 
telomerase, 5) stimulate angiogenesis to provide access to nutrients and oxygen and removal of metabolic 
waste and carbon dioxide and 6) undergo invasion and metastasis whereby tumor cells alter their shape 
and lose their attachment to other cells and to the extracellular matrix (Fig. 1A)2.  
 
 
 
Figure 1. The hallmarks of cancer (A) Schematic representation of the six ‘core’ hallmarks acquired by a tumor cell during its multistep 
development. These six hallmarks are sustaining proliferation, evading growth suppression, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis. (B) Furthermore tumor cells acquire two emerging 
hallmarks, reprogramming energy metabolism and avoiding immune system, and two enabling hallmarks, genome instability and  
tumor-promoting inflammation. (Adapted from reference2) 
 
In addition to these six ‘core’ hallmarks it is now becoming evident that the tumor cells can also acquire a 
number of newly described emerging and enabling hallmarks. The first one is the reprogramming of their 
energy metabolism where tumor cells use glycolysis to produce energy even under aerobic conditions. A 
second is the ability to escape from the immune system. A third is the accumulation of mutations and 
obtaining genome instability, which will result in the selection and expansion of subclones of the tumor 
cells. A forth is tumor-promoting inflammation where normal immune cells infiltrate and attack the tumor 
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cells, but is offset through the resulting inflammation promoting tumor growth by the delivery of growth, 
survival and proangiogenic factors (Fig. 1B)2. In addition a block in differentiation can be assigned as 
another hallmark of cancer, which is caused by the ectopic expression or loss of key transcription factors. 
This block in differentiation contributes to the development of hematologic malignancies by keeping the 
tumor cells in an immature state3,4. 
 
The underlying causes of these cancer hallmarks include both genetic and epigenetic alterations. Genetic 
alterations, such as deletion, amplification, insertion, translocation or point mutations, and epigenetic 
alterations, such as DNA methylation and histone modifications, change the expression levels of the affected 
genes or change their enzymatic activity with the above described consequences for the cell. The genetic 
alterations can be inherited or occur because of exposure to environmental factors, such as tobacco smoke, 
high-fat diet, toxic chemicals or viral infection. These genetic alterations will give the cells a selective 
advantage, which results in their outgrowth in the local tissue. Further accumulation of genetic alterations 
because of genome instability, can then promote tumor cells to acquire increased invasive and metastatic 
potential2. 
 
Of all these processes listed above, the ability of tumor cells to sustain continuous cellular proliferation can 
be achieved through increased protein tyrosine phosphorylation to activate downstream signal transduction 
pathways. This ability of tumor cells to increase protein tyrosine phosphorylation is further studied in this 
manuscript in the context of acute lymphoblastic leukemia and melanoma. 
 
 
1.1 Acute lymphoblastic leukemia 
 
Acute lymphoblastic leukemia (ALL) is a malignant neoplasm arisen either from B-cell or T-cell lineage.  
B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of ALL, while T-cell acute 
lymphoblastic leukemia (T-ALL) accounts for 15-25% of the ALL patients. With the current chemotherapy the 
cure rate is 70-80% in children but only 30-40% in adults. The prognosis of ALL patients with primary 
resistance and relapse is poor and it is necessary to identify new targets for therapy for these patients. In 
addition, despite the fact that most children with ALL survive due to effective chemotherapy regimens, the 
short term and long term side effects of chemotherapy are significant, and it remains of high interest to 
(partially) replace chemotherapy by more specific and less toxic targeted agents. A way to achieve this is to 
further understand the molecular basis of these leukemia – both at genetic and protein level. ALL is a 
complex disease, which is caused by a combination of genetic alterations including translocations, point 
mutations, deletions and epigenetic alterations. When some of these genetic alterations occur at the level of 
the hematopoietic precursor cells, it can cause cellular changes including increased proliferation and 
survival, cell cycle defects, impaired differentiation, unlimited self-renewal capacity and insensitivity to 
apoptotic signals. In regard to both B- and T-ALL, the genetic alterations, and clinical presentation of the 
disease can be markedly different and are further highlighted below5,6. 
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1.1.1 B-cell acute lymphoblastic leukemia 
 
B-ALL is a malignant neoplasm of the B-cell progenitors, which is characterized by hematologic 
abnormalities such as anemia, leukocytosis with neutropenia, thrombocytopenia and rarely eosinophilia. 
Other clinical presentations are lymphadenopathy, hepatosplenomegaly and infiltration in the central nervous 
system5. 
 
B-ALL cases possess a primary genetic alteration, often a chromosomal translocation, followed by the 
accumulation of secondary genetic alterations, affecting proteins involved in cell proliferation and 
differentiation. Chromosomal translocations found in B-ALL include t(1;19)(q23;p13.3) and t(9;22)(q34;q11). 
The t(1;19)(q23;p13.3) translocation results in the formation of a E2A-PBX fusion protein and occurs in 3-5% 
of the B-ALL cases. The E2A-PBX fusion protein functions as a transcriptional activator, which causes 
aberrant gene expression5. The t(9;22)(q34;q11) translocation results in the BCR-ABL1 fusion protein and 
occurs in 25% of the adult B-ALL patients. The BCR-ABL1 fusion protein acts as a constitutive active form of 
the ABL1 tyrosine kinase activity, which promotes cell proliferation5,6. The accumulation of secondary genetic 
alterations, stimulating cell proliferation and blocking B-cell differentiation, is necessary for driving the 
development of B-ALL. The activating mutations in the JAK proteins and the upregulation of the CRLF2  
type I cytokine receptor through translocation are examples of proteins involved in cell proliferation 
pathways5,6. Deletion of the CDKN2A/B cell cycle regulators is present in 30-50% of the B-ALL patients. 
Deletions of the PAX5 and IKZF1 transcription factors, involved in B-cell development, are examples of 
genetic events affecting the B-cell differentiation5-7. 
 
 
1.1.2 T-cell acute lymphoblastic leukemia 
 
T-ALL is an aggressive malignancy of thymocytes, 
which is characterized by high white blood cell 
counts, enlargement of mediastinal lymph nodes and 
frequent infiltration of the central nervous system. 
T-ALL accounts for 10-15% of the pediatric and 25% 
of the adult ALL cases and is more frequent in males 
than in females3,4. 
 
The genetic lesions found in T-ALL can be subdivided 
into five groups characterizing the disease (Fig. 2). 
The first and an important group in T-ALL genetic 
lesions is the one concerning the NOTCH signaling 
pathway. In 60% of the T-ALL samples NOTCH1 is 
activated through mutations and only in 1% of the 
cases by translocation. This uncontrolled activation of 
NOTCH1 contributes to the self-renewal capacity of 
the leukemic cells. The second group involves the 
Figure 2. Schematic representation of the genetic defects  
in T-ALL Genetic lesions affecting the NOTCH signaling 
pathway and the CDKN2A/B cell cycle regulators are central in 
the pathogenesis of T-ALL. Furthermore, genetic alterations 
affecting cell differentiation, cell proliferation pathways and 
epigenetic regulators also contribute to the development of  
T-ALL. (Adapted from De Keersmaecker, unpublished) 
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alterations in cell cycle regulators. Deletions of the CDKN2A locus are present in 70% of the T-ALL 
patients. CDKN2A contains the p16INK4A and p14ARF tumor suppressor genes, which are key regulators in 
the cell cycle. Alterations affecting cell differentiation are assembled into the third group and are often the 
result of ectopic expression of key transcription factors including TAL1, TLX1 and TLX3 and/or conversely 
the loss of RUNX1 and GATA3. The fourth group contains alterations in regulators of chromatin structure 
and includes mutations or deletions of the epigenetic regulators SUZ12 and PHF6. Genetic lesions in 
components of signaling pathways are ranked together into the fifth group. Alterations in this group mainly 
affect cell growth and lineage commitment of the T-cell progenitors3,4. These can include activating mutations 
in the IL7R-JAK/STAT pathway (present in 10% of T-ALL cases) or the loss of the tumor suppressive protein 
tyrosine phosphatases such as PTPN2 and PTPRD, which are further described in this doctoral thesis. 
 
 
1.2 Melanoma 
 
Melanoma is an aggressive malignancy of the melanocytes. During development melanocytes migrate from 
the neural crest to the basal layer of the skin. With their long dendrites melanocytes are connected with the 
keratinocytes located in the epidermis. Melanocytes produce the melanin pigment, which is transported in 
melanosomes to the keratinocytes. Melanin protects the keratinocytes by absorbing and scattering UV 
radiation. A low pigmentation and high sun exposure increase the incidence of melanoma8.  
 
The development of metastatic melanoma is a multistep process starting in the melanocytes. Increased 
proliferation of the melanocytes results in the development of benign nevi or dysplastic nevi8. Metastatic 
melanoma originates in 75% of the cases from transforming melanocytes and only in 25% from existing 
benign nevi9. During the radial growth phase (RGP) the cells grow more laterally, but stay in the epidermis. 
Next, the tumor cells invade the upper layer of the epidermis and the underlying dermis, which is distinctive 
for the vertical growth phase (VGP). Thereafter the tumor will become metastatic8 (Fig. 3).  
 
The several steps in this process are characterized by genetic alterations. Most of the alterations are induced 
by environmental factors, such as UV exposure, but in 8-12% the alterations are inherited. A well-known 
congenital alteration in melanoma is the high amount of polymorphism in the MC1R gene. MC1R is a  
seven-transmembrane G-protein-coupled receptor expressed on melanocytes and involved in the process of 
pigmentation. Allelic variation of the MC1R is responsible for the ‘red hair color’ phenotype and the increased 
risk of developing a melanoma. Another congenital alteration is the loss of the cell cycle regulator CDKN2A 
in 25-40% familial melanoma cases. Loss of the CDKN2A tumor suppressor gene leads to the 
immortalization of the proliferating cells in the dysplastic and benign nevi. Besides the congenital alteration, 
many sporadic alterations are characterized in melanoma. NRAS mutations occur in 10-15% of the 
melanoma samples and BRAF mutations in 60%. The BRAF V600E mutation, which causes the constitutive 
activation of the BRAF kinase, is present in 80% of the BRAF mutations in melanoma. Mutations in the 
BRAF and NRAS kinases are an early event, which drive the proliferation of melanocytes in nevi. In later 
stage of tumor development the tumor cells undergo an epithelial-to-mesenchymal transition (EMT), which is 
a process in which the cells lose their epithelial characteristics and acquire more mesenchymal properties. 
The EMT process is a first step in the acquirement of metastatic potential. The PI3K/AKT pathway is known 
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to be involved in the EMT process. The tyrosine kinase AKT enhances MDM2-mediated degradation of p53, 
which regulates the EMT. Overactivation of AKT occurs either through amplification in 35% of the melanoma 
cases or through loss of the negative regulator PTEN in 37%. Metastatic melanoma has a reduced 
expression of E-cadherin, a protein involved in cell adhesion8,9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Stages of melanoma development Melanocytes are located in the basal layer of the epidermis and with their long dendrites 
they reach the keratinocytes in the superficial layers of the skin. The development of melanoma is characterized by different stages. 
First the amount of melanocytes increases compared to the amount of keratinocytes, which results in the formation of dysplastic or 
benign nevi. Most of these nevi carry BRAF or NRAF mutations, which drive the proliferation of the melanocytes. Loss of the CDKN2A 
cell cycle regulator causes immortalization of the melanocytes. In a next stage, the melanocytes grow laterally in the epidermis, which is 
called the radial growth phase (RGP). This stage is followed by the VGP whereby the cells will invade the upper layer of the epidermis 
and the underlying dermis driven by the epithelial-to-mesenchymal transition (EMT) process. There is evidence that loss of PTEN and 
AKT amplification contribute to this EMT process. The transition from RGP to VGP is assumed to be a critical in the acquirement of the 
metastatic character of the melanoma. In the last stage the tumor cells will migrate because of the acquirement of alterations such as 
downregulation of E-cadherin and which will result in the development of a metastatic melanoma. (Figure based on reference8) 
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Over 90% of the early stage melanoma can be cured by surgery. However, the prognosis of late stage 
melanoma is poor even with chemotherapy. Therefore, many researchers continue to invest further 
understanding the molecular basis of melanoma in order to develop more targeted therapies. Examples are 
the use of tyrosine kinase inhibitors, such as the BRAF V600E specific inhibitor, vemurafenib. Although the 
response is good, overcoming resistance and side effects remains a big challenge8,9. 
 
 
2 Protein tyrosine phosphorylation as an important signal transduction in eukaryotic cells 
 
The human body requires well-defined and regulated communication between cells to function properly. 
Cells respond to both stimuli coming from the environment and from neighboring cells. Environmental signals 
include light or warmth whilst neighboring cells secrete proteins and include cytokines, also called ligands. 
These extracellular signals are often detected by receptors located in the cell membrane, which transmit the 
signal inside the cell. Hereby, a cascade of intracellular signaling proteins is activated, which in the end 
results in a cellular response. This process of transmission of signals in a cell through a range of signaling 
proteins, initiated by an extracellular stimuli and resulting in a cellular response is called signal 
transduction10. 
 
Over the past 60 years it has become clear that protein tyrosine phosphorylation is an important signal 
transduction mechanism which results in several cellular responses including proliferation, survival, 
differentiation, metabolic regulation, motility, adhesion and migration. Here, a phosphate group on a tyrosine 
residue is the link between proteins in these signaling pathways. This process of tyrosine residue 
phosphorylation is a reversible posttranslational modification of proteins regulated by protein tyrosine 
kinases (PTK) and protein tyrosine phosphatases (PTP). PTKs transfer a phosphate group from the ATP 
molecule to the hydroxyl group of the tyrosine residue and thereby generally activate signaling pathways. 
Conversely, PTPs counteract the effect of the PTKs by removing the phosphate group again, which results 
mostly in the inactivation of the pathway10,11 (Fig. 4). 
 
Figure 4. Regulation of protein tyrosine phosphorylation by protein tyrosine 
kinases and phosphatases Protein tyrosine phosphorylation is regulated by the 
counteracting actions of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs). PTKs transfer a phosphate group from the ATP molecule to the 
hydroxyl group of the tyrosine residue. PTPs remove the phosphate group again by 
hydrolysis. 
 
 
 
Protein tyrosine phosphorylation results not only in enzymatically activation of a protein, but can also lead to 
either protein stabilization or conversely mark it for proteasomal degradation. Tyrosine phosphorylation also 
induces protein-protein interactions or leads to protein translocation to another subcellular compartment, e.g. 
the nucleus where the phosphorylated protein can regulate the DNA transcription. It is now becoming clear 
that interruption of this tightly regulated process of protein tyrosine phosphorylation is one of the underlying 
causes of several human diseases like cancer10,11. 
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It should be noted that in addition to tyrosine residue phosphorylation, phosphorylation of serine and 
threonine residues are also well-known signaling transduction mechanisms, and are regulated by protein 
serine/threonine kinases and phosphatases. However, since the main focus in this thesis is tyrosine 
phosphorylation, these mechanisms are not further discussed. 
 
 
2.1 Protein tyrosine kinases 
 
2.1.1 Classification and structure of protein tyrosine kinases 
 
In the human genome 90 protein tyrosine kinases (PTKs) and 5 protein tyrosine pseudokinases were 
identified, which are highly conserved among species12. The 90 PTKs can be classified into 58 receptor 
tyrosine kinases (RTKs) and 32 non-receptor tyrosine kinases (NRTKs). According to the amino acid 
sequences of the kinase domains, the RTK family is further divided into 20 subfamilies and the NRTK family 
into 10 subfamilies13,14 (Fig. 5). The RTKs are located in the cell membrane and contain an extracellular and 
an intracellular part. The extracellular part consists of several globular domains, and can include 
immunoglobulin (Ig)-like domains, fibronectin type III-like domains, cysteine-rich domains or EGF-like 
domains, which are important for ligand binding. With its transmembrane domain the RTKs are retained in 
the cell membrane. The intracellular part consists of a juxtamembrane domain, located just after the 
transmembrane domain, and a catalytic kinase domain14-16. In some RTKs, like the insulin receptor, the 
juxtamembrane domain functions as a binding site for regulatory proteins, but in others, like the PDGFR 
receptors, the juxtamembrane domain has an auto-inhibitory function17. After activation of the RTK through 
ligand binding the catalytic kinase domain will phosphorylate downstream signaling proteins by transferring a 
phosphate group from the ATP molecule. 
 
In contrast to the RTKs, the NRTKs are localized in the cytosol, the nucleus or can be anchored to the cell 
membrane through modifications, such as myristoylation or palmitoylation. Myristoylation is an irreversible 
protein modification whereby the 14-carbon saturated fatty acid myristate is covalently attached to the  
N-terminal glycine residue via an amide bond18. Instead, palmitoylation is a reversible protein modification 
whereby 16-carbon saturated fatty acids are attached to specific cysteine residues through thioester linkage. 
Beside the catalytic kinase domain, the NRTKs contain protein-protein, protein-lipid and protein-DNA 
interaction domains. The most common protein-protein interaction domains found on NRTKs are the SRC 
homology 2 (SH2) and the SRC homology 3 (SH3) domains. The SH2 domain binds to phosphorylated 
tyrosine residues of other proteins and the SH3 domain binds proline-rich peptides. The TEC subfamily 
possesses the pleckstrin homology domain as a protein-lipid domain14. 
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Figure 5. Classification and architecture of the protein tyrosine kinase families Schematic overview of the 90 human protein 
tyrosine kinases (PTKs) subdivided into receptor and non-receptor PTKs. According to their architecture the PTKs are grouped into 
subfamilies (indicated in bold). (Adapted from Porcu, thesis manuscript) 
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2.1.2 Activation of protein tyrosine kinases 
 
2.1.2.1 Activation of receptor tyrosine kinases 
 
With their localization in the cell membrane, the RTKs are involved in mediating the outside-in signaling. 
Their extracellular part can bind ligands, which will result in activation of the RTK. After activation, the 
intracellular part will phosphorylate and so activate downstream signaling proteins in the cytoplasm. In the 
inactive confirmation the RTKs can appear as a monomer (i.e. PDGFR receptors) or preformed oligomers 
(i.e. insulin receptor) in the cell membrane. In the absence of the ligand the RTKs are held in an inactive 
state by cis-autoinhibition of the kinase domain. There are three forms of cis-autoinhibition described. The 
first is the autoinhibition by the activation loop (e.g. as found in the insulin and FGF receptors) where a 
tyrosine residue in the activation loop blocks the active site for binding of ATP and protein substrates. The 
second form of cis-autoinhibition is the autoinhibition by the juxtamembrane (e.g. as found in FLT3, KIT and 
PDGFR receptors), where the juxtamembrane region covers the kinase domain to prevent its activation. The 
third form is the blocking of the active site by the C-terminal tail (e.g. as found in the TIE2 receptor). These  
cis-autoinhibition mechanisms are then overcome upon ligand binding to the extracellular part of the 
receptor, which results in the dimerization of receptor monomers and induces conformational changes in the 
dimer structure. These structural changes then facilitate tyrosine autophosphorylation in the cytoplasmatic 
domain. Hereby, one receptor in the dimer will phosphorylate the tyrosine residues of the other RTK. The 
phosphorylated tyrosine residues of the intracellular part of the RTK form docking sites for the binding of 
cytoplasmic proteins to pursue the downstream signaling14,16. 
 
 
2.1.2.2 Activation of non-receptor tyrosine kinases 
 
NRTKs function in the cytoplasm downstream of the receptor tyrosine kinases. In general, NRTKs are kept in 
an inactive confirmation by inhibitor proteins and lipids and through cis-autoinhibition mechanisms. 
Phosphorylation of the tyrosine residues in the activation loop by RTKs or other NRTKs results in an 
increased kinase activity14,15. The mechanisms of activation can differ between NRTKs and are exemplified 
for the SRC, ABL1 and JAK kinases. 
 
The human SRC family counts eight family members (SRC, LCK, FYN, YES, FGR, HCK, BLK and LYN) and 
all share a similar protein architecture. They contain a myristoylated amino terminus, a region with positively 
charged residues for the interaction with phospholipid head groups, a short region with low sequence 
homology, a SH3 domain, a SH2 domain, a tyrosine kinase domain and a C-terminal tail. The SRC kinases 
contain two important tyrosine phosphorylation residues for the regulation of their activation. The first is the 
Tyr-416 residue located in the activation loop and its phosphorylation is required for fully catalytic activation 
of the SRC kinase. The second regulatory phosphorylation site is Tyr-527 located in the C-terminal tail. 
Phosphorylation of Tyr-527 by the negative regulator and NRTK CSK locks the SRC kinase in a closed 
confirmation through binding of the phosphorylated tyrosine residue with its own SH2 domain. In addition, 
intramolecular interactions between the SH3 domain and the segment linking the SH2 domain with the 
kinase domain, called SH2-kinase linker, stabilize this closed conformation14. 
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The ABL1 kinase is a cytoplasmic and nuclear NRTK that is involved in the regulation of cellular processes 
including cell differentiation, proliferation, adhesion and stress response. Although the structure of the ABL 
kinase resembles that of the SRC kinase, its activity is differently regulated. Instead of regulating the kinase 
activity, the C-terminal region of ABL1 is important for the protein-protein interactions and the subcellular 
localization of the ABL1 kinase. Instead, the SH3 domain of ABL inhibits its kinase activity by binding cellular 
inhibitors, such as PAG14. 
 
The JAK family consists of 4 members (JAK1, JAK2, JAK3 and TYK2), which share a similar architecture 
consisting of a FERM domain, a SH2 domain, a pseudokinase domain and a catalytically active kinase 
domain. With their FERM domains, the JAK kinases are bound to the intracellular part of cytokine receptors, 
which lack intrinsic catalytic activity. Ligand binding to the extracellular part of the cytokine receptor induces 
a conformational change, which brings the JAK kinases in close proximity to enable transphosphorylation 
and activation. The pseudokinase domain is involved in the positive and negative regulation of the kinase 
activity. In the absence of cytokine induction the pseudokinase domain suppresses the basal JAK activity. 
However, the pseudokinase domain is also required for the cytokine inducible activation of the downstream 
signaling. The exact mechanism behind this dual function of the pseudokinase domain is not yet clear14,19. 
 
 
2.1.2.3 Transfer of phosphate-group in the kinase domain 
 
The architecture of the kinase domain is similar in 
all protein kinases and consists of small N-terminal 
lobe (N-lobe) and a large C-terminal lobe (C-lobe). 
The N-lobe contains five β-sheets and one α-helix, 
whereas the C-lobe mainly consists of α-helices. 
The deep cleft formed by the two lobes is the active 
site14,20-22 (Fig. 6). The magnesium or manganese 
cations present in the cleft are important for the 
binding and coordination of the ATP molecule in 
the cleft. The G-loop between the β1- and  
β2-strands, containing three conserved glycines, 
covers the β- and γ-phosphates of the ATP 
molecule and is involved in the phosphoryl transfer 
and the ATP-ADP exchange. The substrate binds to the C-lobe, which brings the substrate in close proximity 
to the ATP molecule in order to facilitate the transfer of the phosphate-group from the ATP molecule to the 
substrate. In the inactive confirmation, binding of ATP and the substrate is impossible, because the 
activation loop is blocking the active site. Phosphorylation of the tyrosine residue in the activation loop will 
remove the activation loop from the active site and makes it accessible for the ATP molecule and 
substrates14,21. 
 
 
 
Figure 6. Structure of tyrosine kinase domain Structure of 
tyrosine kinase domain of SRC family kinases in active (left) and 
inactive (right) conformation. The N-lobe consists of 5 β-sheets 
and 1 α-helix and the C-lobe exists mainly out of α-helices. 
(Adapted from reference22) 
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2.1.3 Mechanisms of protein tyrosine kinase deregulation in cancer 
 
Deregulation of the tightly controlled tyrosine kinase activity contributes to the development of several cancer 
types. In this section we describe four mechanisms that are involved in the deregulation of the PTKs: fusions, 
mutations, increased or aberrant expression of the PTK or its ligand, and loss of negative regulators. These 
alterations can change the subcellular localization of the PTK or alter the signal transduction, which will 
promote cell proliferation and survival, and increase the invasive and metastatic character of the tumor 
cells15,23. 
 
 
2.1.3.1 PTK fusion proteins 
 
Chromosomal translocations can activate a PTK via fusion with a partner protein resulting in its constitutive 
activation of the PTK independent of activating signals by inducing oligomerization, changing the subcellular 
localization or destroying an autoinhibitory domain. A well-described example of a translocation activating a 
PTK via the induction of oligomerization occurs in the BCR-ABL fusion protein. The fusion protein present in 
95% of the chronic myeloid leukemia (CML) cases and in 25% of the adult B-ALL cases. The chromosomal 
translocation t(9;22)(q34;q11.2), also known as the Philadelphia chromosome, fuses the 5’ part of BCR to 
the first intron of the NRTK ABL. The constitutive activation of the ABL kinase is caused by the 
oligomerization through the coiled-coiled domain in the N-terminus of BCR, through the loss of the 
autoinhibitory N-terminal myristoyl group and through binding of the GRB2 adaptor protein. These alterations 
leads ultimately to the phosphorylation of the Tyr-177 residue in BCR and concomitant activation of the 
RAS/MAPK and PI3K/AKT signaling pathways24-26. 
 
Another chromosomal translocation involving the ABL kinase is the generation of the NUP214-ABL1 fusion, 
which is present in 6% of the T-ALL cases. In most T-ALL patients this fusion gene is located on episomes. 
The episomes are formed after deletion and followed by circularization of the 9q34 region between intron 1 
of ABL1 and intron 23-24 of NUP214. The formation of the episomes results in an in-frame fusion of the 
NUP214-ABL1 gene. The episomes are amplified during cell division and can be integrated again in the 
genome. In contrast to BCR-ABL fusion, the kinase activation of the NUP214-ABL1 fusion occurs because of 
the relocalization of ABL to the nuclear pore complex and its interaction with other nucleoporins. The wild 
type NUP214 protein is a nucleoporin in the nuclear pore complex, where it is involved in export of 
macromolecules between the nucleus and the cytoplasm. Because of the N-terminal region of the NUP214, 
the NUP214-ABL1 fusion protein is also localized at the nuclear pore complex. In this complex the  
NUP214-ABL1 fusion proteins are interacting with each other and with other nucleoporins, which results in 
the kinase activation of the fusion protein27-29. 
 
A translocation that results in the loss of a PTK autoinhibitory domain is exemplified by the FIP1L1-PDGFRα 
fusion found in chronic eosinofilic leukemia. In this fusion a truncated juxtamembrane domain of the RTK 
PDGFRα is responsible for the constitutive activation of the FIP1L1-PDGFRα fusion. As described above, 
the juxtamembrane domain can acts as an autoinhibition mechanism in RTKs and therefore the loss or 
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interruption of the juxtamembrane domain results in autophosphorylation and constitutive activation of the 
kinase domain30-32. 
 
 
2.1.3.2 PTK mutations 
 
The occurrence of point mutations, small deletions and insertions in autoregulatory domains of the kinase 
can affect its activity. Mutations in the JAK kinase family members are often identified in hematological 
malignancies. JAK kinases are bound to the cytosolic domains of cytokine receptors, because of the lack of 
intrinsic catalytic activity of these receptors. Cytokine binding will activate the JAK kinases, which in turn will 
phosphorylate the STAT proteins. Phosphorylated STAT proteins will dimerize and translocate to the nucleus 
to regulate gene expression. The JAK2 V617F mutant is present in the majority (95%) of the polycythemia 
vera patients and in 50% of the essential thrombocythemia and idiopathic myelofibrosis. The V617 residue is 
located in the pseudokinase domain of JAK2 and maintains the activation loop in a position where it blocks 
the kinase domain from substrate binding. Substitution of this residue will constitutively activate the kinase, 
which will promote the proliferation of the malignant cells33,34. Mutations in the JAK member have also been 
identified in ALL and AML. Mutations in JAK1 have been reported in 10-20% of the T-ALL cases and 
mutations in JAK3 in 15% of the T-ALL cases. Compared to the high frequency of the JAK2 V617R mutant, 
the JAK1 and JAK3 mutations are spread all over the protein. Depending on the location of the JAK1 and 
JAK3 mutation, the mechanism of constitutive activation of the kinase differs. Mutations in the FERM and 
SH2 domain affect the cytokine receptor binding. Mutations in the kinase and pseudokinase alter ATP and 
substrate binding and coordination35-39. 
 
 
2.1.3.3 Increased or aberrant expression of the PTK or its ligand 
 
The increased or aberrant expression of the PTK or its ligand is another mechanism, which enhances 
cellular signaling. The JAK/STAT pathway is also involved in the development of Hodgkin lymphomas, 
because of an amplified JAK2 locus in 30% of the cases39. Another well-described example of PTK 
activation is the amplification of the RTK HER2/neu, which is amplified in 25-30% of the breast cancers40. 
 
 
2.1.3.4 Loss of PTK negative regulators 
 
Besides the genetic alterations that affect the PTKs directly, loss of their negative regulators can also 
increase their kinase activation. The suppressors of cytokine signaling (SOCS) proteins are part of classical 
negative feedback loop of the JAK/STAT pathways. The STAT proteins induce the expression of the SOCS 
proteins, which bind the JAK proteins as pseudosubstrates, thereby inhibiting the kinase activity41. SOCS 
proteins are frequently mutated in Hodgkin lymphoma and thereby prevent the negative feedback loop 
resulting in the constitutive activation of the JAK2/STAT5 signal transduction pathway39,42. The protein 
tyrosine phosphatases (PTPs) are also negative regulators of PTKs by dephosphorylating their tyrosine 
residues. Examples are loss of the JAK/STAT negative regulators, PTPN2 and PTPRC, in T-ALL43-45. 
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2.1.4 Protein tyrosine kinases as therapeutic targets 
 
Currently chemotherapy remains the treatment of choice for most cancer types. However, although this 
conventional chemotherapy is effective in some cancers, the outcome is often unpredictable or just palliative. 
Moreover, the treated patients suffer from severe side effects including immunosuppression, anemia, hair 
loss, nausea and vomiting. These side effects are mostly due to mechanism of action of chemotherapeutic 
agents and their indiscriminant targeting of all rapid proliferating cells including not only the tumor cells but 
also the normal cells from the bone marrow and the gastrointestinal tract46,47. Therefore there remains a 
strong rationale for developing more targeted therapies, which target specifically cancer specific molecules 
responsible for driving the tumor growth and progression. In this regard, there has been a strong interest on 
developing inhibitors against different family members of PTKs that are frequently mutated and constitutively 
active in cancer and which are often essential for the proliferation and/or survival of the tumor cells48. To date 
there has been the development of two main types of PTK inhibitors: 1) small-molecule drugs and  
2) monoclonal antibodies46. The number of these agents has been increasing steadily over the past decade 
and a few inhibitors have now received a US Food and Drug Administration approval as cancer treatments 
including imatinib mesylate which targets BCR-ABL in CML and trastuzumab which targets HER2 receptor in 
breast cancer48.  
 
Despite the promising results of the PTK inhibitors in patient treatment, there are still some challenges to 
overcome. The major challenge to overcome is the development of drug resistance. Several mechanisms 
have been described that cause drug resistance, such as the induction of secondary mutations that impede 
drug binding, overexpression of the oncogenic PTK or its ligand and upregulation of alternative kinase 
signaling pathways. This has led to the development of a new generation of inhibitors and the use of 
combinatory therapies as ways to circumvent this observed drug resistance15,46,48,49. Although the PTK 
inhibitors are less toxic than the conventional chemotherapy because they target the tumor cells with more 
specificity, still some toxic side effects have been reported due to the inhibition of PTKs in normal cells. 
Therefore, the search for new and more effective therapeutic targets with a higher specificity towards the 
oncogenic target is ongoing15,48. 
 
 
2.1.4.1 Small-molecule PTK inhibitors 
 
The majority of small-molecule PTK inhibitors interfere with the kinase activity by interacting with the  
ATP-binding pocket through the formation of non-covalent hydrogen binding in a competitive manner. Other 
types of inhibitors include the allosteric which bind outside the ATP-binding pocket and covalent inhibitors 
that form irreversible and covalent bonds to the kinase active site48. Of the ATP-competitive inhibitors small 
molecule inhibitors, one of the first commercial and clinical success stories was the development of the drug 
imatinib mesylate (Gleevec), used for the inhibition of the oncogenic BCR-ABL fusion in CML patients. 
However, despite of the good response in many CML patient samples, the occurrence of imatinib resistance 
now presents as a significant clinical challenge50. The main cause of imatinib resistance is the introduction of 
secondary mutations in the ABL kinase domain, which interfere with the binding of imatinib to the  
ATP-binding pocket. A common secondary mutation in the ABL kinase domain is the T315I mutation, also 
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called the gatekeeper mutation, since it both interrupts the hydrogen bond to imatinib and also allosterically 
interferes with the drug binding46,51. Gene amplification and overexpression of BCR-ABL were also 
associated with imatinib resistance. To overcome these resistance mechanisms, a second-generation of 
small-molecule PTK inhibitors is now being developed. One of these agents is the dual SRC-ABL inhibitor 
dasatinib, which binds ABL with less strict conformational requirements than imatinib49. 
 
 
2.1.4.2 Monoclonal antibodies 
 
Monoclonal antibodies are directed against the extracellular part of the RTKs or their ligands, which results in 
a diminished receptor signaling52. Overexpression of HER2 receptor occurs in 25% of the breast cancer 
patients, and these patients are treated with trastuzumab (Herceptin), a monoclonal antibody against the 
HER2 receptor. In combination with chemotherapy, trastuzumab increases the survival of metastatic breast 
cancer patients with 25% compared to patients treated with the cytotoxic chemotherapy alone15,49,52. Another 
example of monoclonal antibodies is cetuximab (Erbitux) directed against the EGFR RTK and used in 
combination with chemotherapy for patients with non-small-cell lung cancer, head and neck cancer and 
colorectal cancer15,49,52. However, parallel to the small-molecule PTK inhibitors, overcoming drug resistance 
and increasing the sensitivity are the major challenges in the development of new monoclonal antibodies. 
 
 
2.2 Protein tyrosine phosphatases 
 
2.2.1 Classification and structure of protein tyrosine phosphatases 
 
Protein tyrosine phosphatases (PTPs) dephosphorylate the tyrosine residues of substrates and thereby form 
the counterbalance of the PTKs, which phosphorylate the tyrosine residues of their substrates. In total there 
are 107 PTPs, but some of them are catalytically inactive or dephosphorylate mRNA or inositol 
phospholipids. This reduces the number to 81 PTPs catalytically active PTPs, which act to dephosphorylate 
phospho-tyrosine residues. This number is comparable with the 85 catalytically active PTKs, highlighting the 
important balance between PTKs and PTPs. According to the amino acid sequence and their catalytic 
domain the PTPs can be grouped into three classes of Cys-based PTPs and one class of Asp-based 
PTPs53,54 (Fig. 7). In contrast to the three cysteine-based PTPs classes, in the class of Asp-based PTPs the 
aspartic acid residue has a central role in the catalytic mechanism54,55. The class I Cys-based PTPs can be 
subdivided into 38 “classical” PTPs, which are strictly tyrosine specific, and 61 dual specificity phosphatases 
(DSPs), which dephosphorylate Tyr and Ser/Thr residues, phosphatidyl inositol phosphates and 
mRNA53,54,56. The “classical” PTPs are further divided in 21 receptor like PTPs (PTPR) and 17 non-receptor 
PTPs (PTPN). Through their location in the transmembrane, the RPTPs can bind a high diversity of ligands 
with their diverse extracellular parts built of immunoglobulin (Ig)-like, fibronectin type III (FNIII) like, 
mephrin/A5/RPTPµ (MAM), carbonic anhydrase-like and/or cysteine-rich domains. The identity and function 
of these ligands are not completely known. The Ig-like, FNIII and MAM regions are also found in cell 
adhesion molecules, predicting a role of PTPR in cell-cell contact57. Out of the 21 PTPR, 12 contain two PTP 
domains. With the exception of PTPRA, only the first domain is catalytically active. The second PTP domain 
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is involved in regulation of the catalytic activity of the first domain, in protein-protein interaction during 
dimerization and in substrate binding. The PTPNs are located in the cytoplasm and consist of one 
catalytically active PTP domain, the SH2 or FERM binding domains and regulatory domains, which control 
the phosphatase activity and subcellular localization53,55,56,58. 
 
 
Figure 7. Classification and architecture of the protein tyrosine phosphates Schematic overview of the human protein tyrosine 
phosphates, which are grouped into four classes according to their amino acid sequence and their catalytic domain. Used abbreviations; 
Coil: coiled-coil domain, GB: glycogen binding, mRC: mRNA capping, PBM: PZD binding motif, pepN: N-terminal peptidase-like, PH-G: 
pleckstrin homology-“GRAM” domain, Pro-rich: proline rich, Sec14: Sec14p homology. A red cross over a PTP domain indicates a 
catalytically inactive domain. (Adapted from reference54) 
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In contrast to the “classical” PTP, the DSPs have less sequence similarity, but they use the same catalytic 
mechanism with a key role for the cysteine residue. Because of alternative active site conformation, the 
DSPs are able to dephosphorylate a broader range of substrates. The DSP can be further divided in 7 
subgroups: MAPK phosphatases (MKPs), atypical DSPs, Slingshots, PRLs, CDC14s, PTENs and 
Myotubularins. The class II Cys-based PTPs contains the Low Molecular Weight (LMW) PTPs, which has 
very low sequence homology compared to the other PTPs, except from active site motif54,58. The  
rhodanese-derived PTPs belong to the class III Cys-based PTPs. They regulate the cell cycle through 
dephosphorylation of the CDKs proteins. In contrast to the Cys-based PTP, an aspartic acid is required in the 
catalytic mechanism of the class IV Asp-based PTPs. To this group belong the EyA phosphatases53,54. 
 
 
2.2.2 Regulation of protein tyrosine phosphatases and mechanism of dephosphorylation 
 
The activity of PTPs is tightly regulated and are not constitutively active housekeeping enzymes as initially 
thought. These different regulatory mechanisms include controlling their ability to dimerize, their 
phosphorylation status, and their oxidative status. The ability of PTPs to dimerize is a known regulatory 
mechanism in many RPTPs, such as PTPRA, PTPRC, PTPRS. When RPTPs are dimerized the  
helix-turn-helix wedge loop from one PTP domain blocks the PTP domain of its partner, which results in the 
inhibition of the catalytic activity. This dimerization may be induced or interrupted by ligand binding. This is in 
sharp contrast with regulation of PTKs, where ligand-induced dimerization results in kinase activity. The first 
evidence that dimerization could regulate PTP activity was found for RPTP using a chimeric protein in  
T-cells. The chimera contained the extracellular part of the EGFR kinase and the intracellular part of PTPRC. 
Dimerization of the chimera was induced after addition of the EGF ligand, which resulted in a reduced T-cell 
response due to inactivation of the chimera. A second mechanism to regulate PTP activity is via 
phosphorylation. An example includes the regulation of PTPRA activity, which is activated after 
phosphorylation of the two serine residues in the juxtamembrane domain. Here, phosphorylation of the two 
serine residues results in disruption of the inactive dimer confirmation, since the serine residues are closely 
located to the helix-turn-helix wedge loop. Finally, the phosphatase activity of the “classical” PTPs including, 
cdc25c, PTEN and LMW-PTPs are negatively regulated by oxidation. The cysteine residue in the active site 
of the PTPs is highly sensitive to oxidation because of its thiolate state (S-). Oxidation of this nucleophilic 
cysteine results in a conformational change that abolishes the substrate binding. The oxidation is mainly 
caused by the formation of reactive oxygen species (ROS) in the cell, but also UV-radiation, cell adherence 
and density can stimulate oxidation55,59,60. 
 
Once active, the PTPs can dephosphorylate their substrates through hydrolysis. Here we describe the 
catalytic mechanism of Cys-based PTPs (Fig. 8). All Cys-based PTPs contain a phosphate binding loop or  
P-loop with the PTP signature motif (H/V)C(X)5R(S/T) in their active site. In a first step, the thiolate side chain 
of the cysteine residue in the P-loop functions as a nucleophile by the donation of an electron pair to accept 
the phosphoryl group from the substrate. The arginine residue in the P-loop forms two hydrogen bonds with 
the phosphoryl group through its guanidinium group to stabilize the substrate binding. The WPD loop closes 
around phospho-tyrosine. The aspartic acid residue in the WPD loop behaves as an acid by protonating the 
tyrosyl group of the substrate. This will result in the demerger of the substrate. In a second step, the release 
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of the phosphate occurs by hydrolysis of the cysteinyl-phosphate intermediate. Hydrolysis is mediated by the 
glutamine of the Q-loop, which coordinates the nucleophilic water molecule, and the aspartic acid of the 
WPD-loop, which acts now as a general base55,58,61. 
 
 
Figure 8. Catalytic mechanism of Cys-based protein tyrosine phosphatases The catalytic mechanism of Cys-based PTPs occur in 
two steps. In the first step the thiolate side chain of the cysteine residue in the P-loop donates an electron pair to the phosphoryl group 
of the substrate. For stabilization of the substrate binding the arginine residue in the P-loop forms two hydrogen bonds with the 
phosphoryl group. The aspartic acid residue in the WPD loop protonate the tyrosyl group of the substrate. This results in the release of 
the substrate. In a second step the phosphate is released through hydrolysis. Therefore, the glutamine of the Q-loop coordinates the 
nucleophilic water molecule and the aspartatic acid of the WPD-loop behaves now as a base. (Adapted from reference61) 
 
 
2.2.3 Protein tyrosine phosphatases in cancer 
 
PTKs together with PTPs control the balance of tyrosine phosphorylation, which is important for downstream 
signal transduction and regulation of several cellular processes such as proliferation, survival, differentiation, 
adhesion and migration. Disruption of this tightly regulated balance contributes to the development of human 
diseases, such as cancer. As described above, deregulation of this balance can occurs on one hand through 
disturbance of the PTK activity, which promotes tumor development. On the other hand, more insight has 
been acquired in the contribution of altered PTP activity in the development of cancer. Here, we describe 
some examples of genetic and epigenetic alterations of PTP genes in cancer. 
 
 
2.2.3.1 Genetic alterations 
 
Genetic alterations affecting PTP genes include deletions, loss of heterozygosity (LOH), amplifications and 
mutations56,62,63. The most commonly lost PTP in many cancer types through genetic alterations is PTEN. 
The DSP PTEN inhibits cell proliferation and survival by inactivating the PI3K pathway. In general, PTEN is 
mutated in 15% of cancers, with a higher mutation rate in glioblastoma multiforme (GBM) (30-40%) and 
endometrial carcinoma (50%). LOH is also found at high frequency for many cancers including 40-55% in 
endometrial carcinoma, 50-70% in GBM, 31% in breast cancer and 47% in lung tumors64,65. In addition to 
PTEN, several other PTP family members have also been found to frequently deleted or amplified in human 
cancers. For example, PTPN2 is deleted in 6% of the T-ALL cases43 and PTPRD is deleted in several types 
of cancer such as GBM and neuroblastoma66-70. 
 
Introduction 
 30 
Inactivation of the PTPs by point mutations can also contribute to the development of cancer. The PTPRT 
phosphatase, for example, is mutated in 17% of the lung and gastric cancers and in 26% of the colorectal 
cancer71,72. The point mutations in the catalytic domains of PTPRT cause a reduced phosphatase 
activity62,71. As mentioned above, the members of the RPTP have already described roles in cell adhesion. 
Hence mutations in RPTP not only interfere with their phosphatase activity, but mutations in these RPTPs 
also promote tumor progression by affecting their adhesion function. Crystal structures of PTPRM 
phosphatase showed that mutations can reduce the adhesiveness by disrupting the homophilic interactions 
or affecting the protein folding or processing73. 
 
It should be noted that although the majority of PTPs behave as tumor suppressors as a function of their 
ability to inactivate the PTK signaling pathways, activating point mutations and gene amplification could 
contribute to the oncogenic character of some PTPs. For instance, the PTPN1 phosphatase gene is 
amplified in epithelial cancers, PTPN7 in leukemia and myelomas and PTP4A3 in metastatic colorectal 
cancers62. The PTPN11 phosphatase gene is mutated in 35% of the patients with juvenile myelomonocytic 
leukemia. However in this case PTPN11, which normally regulates activation of the RAS pathway by 
dephosphorylating the negative regulators, CSK and the RAS-GTPase activating protein (RASGAP), the 
acquired mutations enhance the PTPN11 affinity for phospho-tyrosine peptides to increase the PTP activity 
resulting in an enhanced RAS signaling74-77.  
 
 
2.2.3.2 Epigenetic alterations 
 
The most common epigenetic alteration resulting in gene silencing is the DNA methylation of the CpG 
islands62. Reduction in gene expression because of DNA methylation was observed for PTPRG in 27% of 
the cutaneous T-cell lymphoma78, for PTPRO in 82% of the chronic lymphocytic leukemia79 and for PTPN13 
in 50% of the hepatocellular carcinoma80. 
 
 
2.2.4 Protein tyrosine phosphatases as therapeutic targets 
 
As well as PTKs, PTPs are also gaining interest as therapeutic targets because of their involvement in 
several diseases. Nevertheless many compounds targeting oncogenic PTP have not yet made it to the 
clinics due to a number of challenges in this research field. One of the major problems is specific targeting 
the active site of single PTPs because of the high level of homology in catalytic domains between the 
different PTP family members. In addition, potential drugs often contain oxidizing agents, which leads to the 
oxidation of the PTPs56,62. Yet, the industry has been able to develop a potent, specific and reversible 
inhibitor for PTP1B, which is the nonhydrolyzable pTyr-mimetics. One disadvantage of this compound is the 
high charge, which reduced its oral bioavailability56,81. The development of allosteric inhibitors would 
overcome these problems, because these compounds bind outside the active site inducing a conformational 
change, which will result in the inhibition of the phosphatase activity56,62. An alternative strategy to small 
molecule inhibitors is the use of antisense-based therapeutics, which have the advantage of higher 
specificity due to being sequenced based. In this instance, an antisense-based therapeutic targeting PTP1B 
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has shown high efficacy in clinical trials for type II diabetes56,81. However, before more therapeutic agents 
can be designed, it is imperative that a greater understanding occurs for the functional role of PTPs in cell 
biology and their contribution to the development of diseases. A single PTP can regulate several signaling 
pathways in a cell or contain multiple effects. A PTP can stimulate or inhibit signaling pathways depending 
on its cellular context. Several PTPs can also work together in the regulation of a signaling pathway. 
Therefore, understanding the signaling pathways controlled by tumor suppressive PTPs will help to identify 
possible targets for therapy. For example, loss of PTPN2 results in an increased activation of the  
NUP214-ABL1 kinase and the JAK/STAT pathway, which are proven to be therapeutic targets in the 
treatment of ALL43,44. 
 
 
2.2.5 Protein tyrosine phosphatase receptor delta 
 
2.2.5.1 Structure and regulation 
 
The Protein Tyrosine Phosphatase Receptor Delta (PTPRD) 
protein is a member of the leukocyte common antigen-related 
(LAR) family of proteins. The PTPRD gene is located on the 
p-arm of the human chromosome 9 (9p23-24.1). The 
extracellular part of PTPRD exists of three Ig-like domains 
and four to eight FNIII domains, depending on the isoform. 
The long isoform contains eight FNIII domains, whereas the 
short isoform lacks FNIII domain 5 to 7. The short isoform is 
mainly expressed in the brain82,83. Further, several transcripts 
of the short isoform have been identified lacking a few amino 
acids in the extracellular domain. Probably the variation in the 
extracellular part is involved in the binding of different 
ligands82. Segregated from the extracellular part by a 
transmembrane domain, the intracellular part contains two 
phosphatase domains of which only the first one is 
catalytically active (Fig. 9). The identity and the functional role 
of the ligands of PTPRD are not yet known. In neurons 
PTPRD is involved in cell-cell adhesion by the heterophilic 
binding of netrin-G-ligand and by the formation of homophilic 
bindings with the PTPRD proteins expressed on the 
neighboring cells84-87. 
 
The regulation of the PTPRD phosphatase activity is not yet understood. It is not clear whether the 
phosphatase activity is inhibited by ligand-binding induced dimerization of the receptor as shown for PTPRS 
and PTPRA55,59,60. What is known is that LAR family members undergo a posttranslational proteolysis, 
similar to the proteolytic cleavage of the NOTCH receptor. As such, the PTPRD protein is cleaved in the 
Golgi by a furine-like protease and both parts are held together by a non-covalent interaction82,84. Three 
Figure 9. Schematic representation of the PTPRD 
isoforms The long and short isoforms of PTPRD are 
located in the cell membrane and differ in the amount 
of fibronectin type III (FNIII) like domain of their 
extracellular part. Both isoforms have three Ig-like (Ig) 
domains extracellular and contain intracellular two 
phosphatase domains (PTP) of which only the first 
one is catalytically active. 
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potential furin-like cleavage sites (RXXR) are located in the extracellular part of PTPRD close to the 
transmembrane domain, but to date it is not yet known which furin-like protease is involved in the cleavage 
process. Once PTPRD has travelled to the cell membrane, another proteolytic cleavage event occurs on the 
extracellular side adjacent to the transmembrane resulting in the release of the extracellular part. Next, the 
remaining 85 kDa transmembrane protein is cleaved on the intracellular side resulting in the release of a  
75 kDa intracellular part82,84,88 (Fig. 10). These extracellular and intracellular cleavage events are likely to be 
processed by an ADAM metalloprotease and γ-secretase complex respectively, because cleavage of the 
structural related PTPRM and PTPRK proteins occurs by the same protease89,90. 
 
 
Figure 10. Proteolytic cleavage of PTPRD After cleavage in the Golgi by a furin-like protease both parts are held together by a  
non-covalent interaction. The PTPRD protein is transported to the cell membrane where it is cleaved in its extracellular part near by the 
transmembrane domain. Thereafter the protein is cleaved intracellular which results in the release of the intracellular part. The exact 
proteases involved in this cleavage process are not yet identified, but the ADAM proteases and the γ-secretase are potential 
candidates. 
 
 
2.2.5.2 Biological role of PTPRD in neurons 
 
The functional role of PTPRD in neural development and physiology has been extensively studied due to its 
high expression in the brain. The PTPRD protein promotes synapse formation between axons and dendrites. 
Present on the presynapse, PTPRD binds with its extracellular part to postsynaptic proteins, including  
NGL-3, IL1RAPL1 and the Slitrks proteins. These interactions induce pre- and postsynaptic differentiation, 
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which results in the formation of an excitatory synapse. Only binding of PTPRD with Slitrk-3 will induce the 
formation of an inhibitory synapse. Presynaptic differentiation is mediated by the binding of Liprin-α or MIM 
with the second phosphatase domain of PTPRD87,91-93. Homophilic interactions between PTPRD proteins 
promote neuronal adhesion and neurite growth in chicken neurons86. The long isoform of PTPRD has been 
found to promote neuronal adhesion, whereas the short isoform promotes neurite growth, with this latter 
function dependent on the phosphatase activity94-96. 
 
The functional importance of PTPRD in brain is also evident from the observed neurological problems in the 
Ptprd-/- mice. The Ptprd-/- mice exhibit motorial dysfunction, spatial learning impairment and enhanced  
long-term potentiation in the hippocampus. Because of their impaired spatial learning it is necessary to place 
the food on the floor of their cages to avoid lethality because of reduced food intake97,98. The possible role of 
PTPRD dysfunction in human neuronal disorders has not yet been demonstrated. However, in a  
genome-wide association study the PTPRD locus was associated with the restless leg syndrome99,100. 
 
 
2.2.5.3 Role of PTPRD in cancer 
 
Genetic alterations in the PTPRD gene, including mutations, deletions and promoter methylation, have been 
described in several cancer types. The PTPRD gene is deleted in 12% of neuroblastomas66,68, in 37% of 
metastatic cutaneous squamous cell carcinomas101,102, in 40% of GBM69,70, in 20% of head and neck cancers 
cell lines, in 11% of lung cancer cell lines103 and in 4% of primary lung cancer samples. Mutations in the 
PTPRD gene are observed in 37% of metastatic cutaneous squamous cell carcinomas101,102, in 6% of GBM, 
in 13% of head and neck cancers70, in 6-9% of lung cancers103-106 and in 12% of melanomas69,107,108. 
Reduced PTPRD expression because of promoter methylation occurs in 37% of GBM70 and in high-grade 
breast cancers and colorectal cancers109,110. 
 
Functional studies have established that PTPRD has a growth suppressive role in human cancer cells. 
Reconstitution of PTPRD in GBM, melanoma and neuroblastoma cell lines suppresses cell proliferation and 
increases apoptosis, whereas shRNA-mediated knockdown of PTPRD results in an increased cell growth. 
The PTPRD mutants are less potent in suppressing cell growth compared to wild type in these cancer cell 
lines69,70,111. The regulation of the cell proliferation by PTPRD is ascribed to its dephosphorylation of the 
STAT3 transcription factor, which is involved in many proliferation pathways70,109. The AURKA kinase is 
another substrate of PTPRD identified in neuroblastoma cell lines. The AURKA kinase is a regulator of the 
cell cycle, which is involved in the formation of microtubule and stabilization of the MYCN oncogene. 
Dephosphorylation of AURKA by PTPRD results in the destabilization of the kinase and consequently of the 
MYCN oncogene, which is frequently amplified in neuroblastoma111. In addition to the regulation of cell 
proliferation, PTPRD can control cell migration. In colorectal cell lines, siRNA-mediated knockdown of 
PTPRD promotes cell migration independent of the catalytic activity. The β-catenin/TCF signaling and the 
CD44 expression mediate the cell migration suppression by PTPRD. The cytoskeletal regulators, Liprin-α 
and MIM, are assumed to be involved in the regulation of migration, because they are able to bind the 
second phosphatase domain92,93,112. Recently it was shown that heterozygous loss of Ptprd cooperates with 
Cdkn2a deletion in tumor formation in a glioblastoma mouse model. The Ptprd+/-p16-/- mice had worse 
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survival outcome and developed a bigger tumor with an increased pSTAT3 level compared to the  
Ptprd-/-p16-/- and Ptprd+/-p16+/+ mice. This increase in tumor volume was not caused by increased cell 
proliferation, but was due to the increase in protumor macrophages113. Considering the observed  
(epi-)genetic alteration in PTPRD together with the functional data, PTPRD seems to be a candidate tumor 
suppressor gene in the development of several cancer types. 
 
 
2.2.6 Protein tyrosine phosphatase, non-receptor type 2 
 
2.2.6.1 Structure and isoforms 
 
PTPN2 is an intracellular, non-receptor protein tyrosine phosphatase, located on the p-arm of the human 
chromosome 18 (18p11.2-11.3). Although PTPN2 initially was isolated from a human T-cell cDNA library, 
and therefore also named T-cell protein tyrosine phosphatase (TC-PTP), the phosphatase is ubiquitously 
expressed in embryonic and adult tissues with a predominant expression in the hematopoietic tissues114-117. 
Alternative splicing at exon 9 results in the expression of a 45 kDa (TC45) and a 48 kDa (TC48) isoform, 
which differ in their C-terminus (Fig. 11). The TC45 contains at its C-terminus a nuclear localization signal 
(NLS), which is responsible for its localization in the nucleus. The nuclear pore complexes import TC45 in the 
nucleus, but stress induces the exit by passive diffusion. The TC48 is located in the endoplasmic reticulum, 
because the NLS sequence is masked through a hydrophobic sequence at the C-terminus, which prevents it 
from nuclear import. Because of their difference in subcellular localization, TC45 and TC48 have different 
substrates117-120. For example, TC48 dephosphorylates BCR-ABL and RTKs such as EGFR, the insulin 
receptor and the MET receptor. The TC45 isoform dephosphorylates proteins present in the nucleus, such 
as STAT proteins, but because TC45 is also present in the cytoplasm it also dephosphorylates RTKs, such 
as the insulin receptor, EGFR, PDGFR and VEGFR116,117. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Structure of PTPN2 Schematic representation of the two PTPN2 isoforms, TC45 and TC48, which differ in their carboxyl 
terminus due to alternative splicing at exon 9. The 45 kDa isoform TC45 consist of a nuclear localization signal (NLS), whereas the 48 
kDa isoform TC48 contains a hydrophobic tail which masks the NLS sequence. 
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2.2.6.2 Role of PTPN2 in immune response and diseases 
 
The study of PTPN2 loss in Ptpn2 knockout models showed evidence of the role of PTPN2 in immune 
response and its link with human immunological diseases. Because of the high expression in hematopoietic 
cells, it is not surprising that the Ptpn2 knockout mice have defects in several hematopoietic lineages. They 
suffer from severe anemia and systemic inflammation, characterized by increased cytokines levels, which 
cause their death 3-5 weeks after birth117,121. The involvement of PTPN2 in the T-cell response was studied 
in more detail in the Lck-Cre; Ptpn2fl/fl mice. The T-cell receptor (TCR) signaling was elevated and they also 
had increased levels of proinflammatory cytokines. The CD8+ T-cell response was enhanced after 
stimulation with low affinity antigens that otherwise could not induce T-cell activation and proliferation122. The 
genome wide association study point out an association between the PTPN2 locus and the susceptibility to 
three autoimmune diseases (Crohn’s disease, rheumatoid arthritis and type 1 diabetes) because of the 
identification of single nucleotide polymorphisms (SNPs). The Ptpn2-/- mice have many immune phenotypic 
characteristics also seen in the human Crohn’s disease. Examples are diarrhea, high expression of the  
IFN-γ, TNF-α and IL-12 cytokines and increased sensitivity to intestinal bacteria117. The contribution of 
PTPN2 in type I diabetes can be ascribed to its regulation of the insulin receptor117,123-128. The fragile bones 
of the Ptpn2-/- mice and the elevated cytokine levels suggest a role of PTPN2 in the development of 
rheumatoid arthritis, although the exact mechanism is not understood117. 
 
 
2.2.6.3 Role of PTPN2 in T-cell acute lymphoblastic leukemia 
 
Besides its role in immune responses and diseases, loss of PTPN2 in 
hematopoietic cell also contributes to the development of hematological 
malignancies. Sequence analysis revealed PTPN2 inactivation in T-cell 
non-hodgkin lymphoma at low frequency129. Deletions of PTPN2 are 
identified in 6% of the T-ALL cases and are specifically associated with 
ectopic expression of the homeobox transcription factor TLX1 in 33% of 
these cases. Loss of PTPN2 causes increased JAK/STAT phosphorylation 
after stimulation of the IL-2 and IL-7 receptors in leukemic cells, but was not 
sufficient to transform these cells43,44. The identification of JAK1 and JAK3 
kinases as substrates of PTPN2 was shown earlier in substrate trapping 
experiments130. These data have shown that PTPN2 is a negative regulator 
of the IL-7 receptor pathway, which is an important proliferative pathway in 
T-cells131 (Fig. 12). Overexpression of oncogenic kinases, such as  
NUP214-ABL1 and JAK1 mutants, together with knockdown of PTPN2 
accelerate the transformation of the leukemic cells. Co-precipitation of the 
NUP214-ABL1 fusion with the catalytic inactive PTPN2 mutant D182A 
indicates NUP214-ABL1 as a direct substrate of PTPN2. Loss of PTPN2 prolonged the survival of a 
NUP214-ABL1 expressing leukemic cell line after treatment with imatinib. Knockdown of PTPN2 in leukemic 
cell lines expressing a JAK1 mutant are also less sensitive to JAK inhibitors43,44. 
  
Figure 12. The IL-7 receptor 
pathway The non-receptor 
protein tyrosine phosphatase, 
PTPN2, is a negative regulator of 
the JAK/STAT pathway 
downstream of the IL-7 receptor 
in T-cells. 
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CHAPTER II – RATIONALE AND AIMS 
 
Protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) are enzymes involved in 
controlling tyrosine phosphorylation and dephosphorylation respectively. As such, they play integral roles in 
regulating the activity of almost all signal transduction pathways. Deregulation of the tightly controlled 
balance between tyrosine phosphorylation and dephosphorylation is known to be an important contributing 
factor in cancer development. The mechanisms resulting in constitutive activation of oncogenic PTKs have 
been intensively studied during the last few decades. There is now accumulating evidence that PTPs also 
contribute in the development of cancer, either as a tumor suppressor or as an oncogene. 
 
It has been established that the constitutive activation of oncogenic PTKs results in the transformation of 
cytokine dependent cultured cells, which makes them an interesting model to study the transforming capacity 
of newly identified PTK mutants and to screen for drug compounds targeting the oncogenic PTKs. Our first 
aim was to use this transforming capacity of oncogenic PTKs in a cytokine dependent cell line to develop a 
screening system for the selection of functional RNAi molecules. 
 
In acute lymphoblastic leukemia, there are numerous activated oncogenic PTKs identified including JAK and 
ABL1. However, little is known about which PTPs are deregulated during ALL progression. Since the PTPRD 
phosphatase is described to be lost in several types of solid cancer, including melanoma, our second aim 
was to determine whether genetic alterations of PTPRD also contribute to the pathogenesis of ALL. Next to 
our study in ALL, we also investigated the role of PTPRD as a tumor suppressor in melanoma to gain more 
insights in its functional role. Previously, the PTPN2 phosphatase is identified as a tumor suppressor in ALL, 
which negatively regulates the JAK/STAT pathway. Our third aim was to identify other signaling pathways 
controlled by PTPN2 in the development of T-ALL. 
 
In more detail we aimed to: 
 
1. Develop a siRNA and shRNA screening system based on a kinase fusion protein 
Although RNAi design algorithms have improved over the last years, it is still a challenge to identify effective 
and specific siRNAs and shRNAs, and this is sometimes further complicated by the difficulty of transfection 
or transduction of the cells of interest. It was my first aim to develop an easy cell-based system that would 
allow the identification of effective siRNA and shRNA molecules in one specific cell line that is easy to 
transduce and to transfect.  
 
 
2. Study a possible tumor suppressive role of PTPRD in ALL and melanoma 
The tyrosine phosphatase gene PTPRD is described to be a candidate tumor suppressor gene in several 
solid cancers, because it is frequently inactivated by genetic and epigenetic alterations. Unfortunately, gene 
expression and functional data are lacking to prove this assumption and the contribution of PTPRD in the 
pathogenesis of ALL was not investigated. 
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Therefore, the aim of this part is to: 
A. Study the role of PTPRD as a tumor suppressor in ALL 
To determine the frequency of genetic alteration in ALL, I analyzed copy number variations (CNV) 
and mutations in ALL patient samples and cell lines. The correlation between CNV and the 
expression levels were defined after analysis of gene expression profiles. The role of PTPRD in 
hematopoiesis was investigated by analyzing the gene expression in human hematopoietic cells and 
by studying morphological changes in hematopoietic tissues in the Ptprd knockout mouse model. 
 
B.  Study the role of PTPRD as a tumor suppressor in melanoma 
PTPRD is frequently mutated (in 12% of the cases) in melanoma, but it remains unclear whether the 
mutations identified are true loss-of-function mutations or rather passenger mutations induced by UV 
exposure. To answer this question, I performed a comprehensive mutation and expression analysis. 
To identify unknown substrates of PTPRD and to define the phosphatase activity of the PTPRD 
mutants identified in melanoma, I performed transfections and protein analysis in 293T cells. 
 
 
3. Identify other signaling pathways controlled by PTPN2 in T-ALL 
PTPN2 is already validated as a tumor suppressor gene in T-ALL, where it negatively regulates the 
JAK/STAT pathway. It was my aim to identify other signaling pathways affected by loss of PTPN2 in T-ALL 
using phospho-proteomics. Of the identified proteins, I focused on PTK2B, a tyrosine kinase that is known to 
be functioning downstream of the IL-7 receptor pathway. Since the IL-7 receptor pathway is involved in T-cell 
proliferation, I investigated the link between PTK2B and the IL7-R pathway and in which cellular response 
PTK2B is involved. 
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CHAPTER III – MATERIALS AND METHODS 
 
Cell lines and patient samples 
 
Expression analysis and CNV were analyzed in 57 human melanoma samples (UZ Leuven – KULeuven), 12 
mouse melanoma samples (VIB – KULeuven), 5 human melanoma cell lines, 13 B-ALL samples (UMC St 
Radboud) and 18 ALL cell lines. All human samples were obtained according to the guidelines of the ethic 
committee (S55073). Functional studies were performed in 293T cells, the IL-3 dependent mouse pro-B cell 
line Ba/F3 and the IL-2/IL-7 dependent mouse T cell line MOHITO. The 293T cells were cultured in RPMI-
1640 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Life Technologies), the 
Ba/F3 cells in RPMI-1640 medium supplemented with 10% FBS and 1 ng/ml IL-3 (Peprotech Inc.), and the 
MOHITO cells in RPMI-1640 medium supplemented with 20% FBS and 5 ng/ml IL-2 and 10 ng/ml IL-7 
(Peprotech Inc.). Ba/F3 cells and MOHITO cells transformed by oncogenic kinases did not require cytokines 
for their growth. 
 
 
Histopathological analysis 
 
The spleen tissues of the mice were isolated and overnight incubated with formaline (Sigma-Aldrich). After a 
washing step with PBS (Life Technologies), the tissue sections were stained with hematoxylin and eosin 
(H&E) according to standard procedures by the lab of prof. T. Tousseyn. Histological images were obtained 
using the Leica DM2500 microscope (Leica microsystems). 
 
 
qPCR and qRT-PCR 
 
RNA and DNA were extracted from patient samples, tissues and cell lines using the Maxwell 16 Instrument 
System (Promega). Tissues were first homogenized with the TissueLyser TL (Qiagen). cDNA was 
synthesized from the RNA samples with the GoScript Reverse Transcriptase (Promega). GoTaq qPCR 
Master Mix (Promega) was used for the performance of quantitative (real-time) PCR with the LightCycler 480 
Real-Time PCR system (Roche Diagnostics) or the ViiA (Applied Biosystems). Data were analyzed with the 
qBase+ software (Biogazelle). 
 
 
Analysis of cancer genomics datasets 
 
CNV analysis of publically available array comparative genomic hybridization (CGH) datasets was performed 
with the Agilent genomic workbench software and with the OmicSoft Array Studio software.  
Mutation analysis of the publically available melanoma datasets was performed with the cBioPortal online 
web tool from the TCGA group. Gene expression profiles were studied with the cBioPortal, the Oncomine 
and the GeneVestigator online available web tools. 
 
Materials and methods 
 40 
Constructs 
 
A myc-tagged truncated version of PDGFRα (tPDGFRα) was cloned in the MSCV-puro vector (Clontech). 
The coding sequences of mouse Pten and Cdkn2a (p16) were amplified by PCR and cloned into the  
MSCV-puro vector containing already tPDGFRα. The CmiR3 vector was generated by cloning the mir30 
backbone in the MSCV-GFP vector. The PTPRD constructs were purchased from Addgene. 
 
 
shRNA and siRNA 
 
The shRNA-Pten-4 was purchased from Open Biosystems. All the other shRNAs targeting Pten and p16 
were designed using the online available RNAi Central 
(http://katahdin.cshl.org/homepage/siRNA/RNAi.cgi?type=shRNA) and the oligonucleotide sequences were 
purchased from Integrated DNA Technologies (IDT). All shRNAs were cloned into the CmiR3 vector. The 
siRNAs targeting Pten and p16 named with a letter were pre-designed RNAi molecules purchased from IDT. 
The siRNAs named with a number were custum-synthesized RNAi molecules designed with the RNAi design 
tool from IDT. The siRNA Ptk2b-A and the siRNA Jak1 were purchased from Ambion and the siRNA Ptk2-B 
from Invitrogen. As negative control, scrambled siRNAs from the same companies were used. The 
sequences of the shRNAs and siRNAs are listed in Table 1 and 2. 
 
Table 1. Sequences shRNAs 
shRNA Top sequence 
Pten-2 AACAATGAACCTGATCATTATATAGTGAAGCCACAGATGTATATAATGATCAGGTTCATTGTC 
Pten-3 CTCTGTGAAGATCTTGACCAATTAGTGAAGCCACAGATGTAATTGGTCAAGATCTTCACAGAA 
Pten-4 CCGACTTAGACTTGACCTATATTAGTGAAGCCACAGATGTAATATAGGTCAAGTCTAAGTCGA 
p16-1 CGCAGCTCTTCTGCTCAACTACTAGTGAAGCCACAGATGTAGTAGTTGAGCAGAAGAGCTGCT 
p16-2 ATTGGTCACTGTGAGGATTCAGTAGTGAAGCCACAGATGTACTGAATCCTCACAGTGACCAAG 
p16-3 AGCTCTGGCTTTCGTGAACATGTAGTGAAGCCACAGATGTACATGTTCACGAAAGCCAGAGCG 
 
Table 2. Sequences siRNAs 
siRNA Top sequence Bottom sequence 
PDGFRα  GGAUUCUACUUUCUACAAUAAGATC GAUCUUAUUGUAGAAAGUAGAAUCCAC 
Pten-A UGAUAUCAAAGUAGAGUUCUUCCAC GUGGAAGAACUCUACUUUGAUAUCACC 
Pten-1 GGUGUAUACAGGAACAAUAUUGATG CAUCAAUAUUGUUCCUGUAUACACCUU 
Pten-2 GAGGCUAGCAGUUCAACUUCUGUGA UCACAGAAGUUGAACUGCUAGCCUCUG 
Pten-3 AGCUAAAGGUGAAGAUAUAUUCCTC GAGGAAUAUAUCUUCACCUUUAGCUGG 
Pten-4 GGGACGGACUGGUGUAAUGAUUUGT ACAAAUCAUUACACCAGUCCGUCCCUU 
Pten-5 CCCACCACAGCUAGAACUUAUCAAA UUUGAUAAGUUCUAGCUGUGGUGGGUU 
Pten-6 GGGUAAAUACGUUCUUCAUACCAGG CCUGGUAUGAAGAACGUAUUUACCCAA 
Pten-7 CAGCCAUCAUCAAAGAGAUCGUUAG CUAACGAUCUCUUUGAUGAUGGCUGUC 
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Pten-8 GCCUGUGUGUGGUGAUAUCAAAGTA UACUUUGAUAUCACCACACACAGGCAA 
Pten-9 GGGAUUUCCUGCAGAAAGACUUGAA UUCAAGUCUUUCUGCAGGAAAUCCCAU 
p16-A UCAAGACAUCGUGCGAUAUUUGCGT ACGCAAAUAUCGCACGAUGUCUUGAUG 
p16-B GGCAACGUUCACGUAGCAGCUCUTC GAAGAGCUGCUACGUGAACGUUGCCCA 
p16-C CAACUACGGUGCAGAUUCGAACUGC GCAGUUCGAAUCUGCACCGUAGUUGAG 
p16-D ACGGGCAUAGCUUCAGCUCAAGCAC GUGCUUGAGCUGAAGCUAUGCCCGUCG 
p16-E CUACCUUCUCCCGCCCGGUGCACGA UCGUGCACCGGGCGGGAGAAGGUAGUG 
p16-1 GCUCAACUACGGUGCAGAUUCGAAC GUUCGAAUCUGCACCGUAGUUGAGCAG 
p16-2 AGGCUAGAGAGGAUCUUGAGAAGAG CUCUUCUCAAGAUCCUCUCUAGCCUCA 
p16-3 GCAGGUUCUUGGUCACUGUGAGGAT AUCCUCACAGUGACCAAGAACCUGCGA 
p16-4 CUCUGGCUUUCGUGAACAUGUUGTT AACAACAUGUUCACGAAAGCCAGAGCG 
p16-5 UCCUGGACCAGGUGAUGAUGAUGGG CCCAUCAUCAUCACCUGGUCCAGGAUU 
Jak1 CCAGUGGCGGCAGAAACCAAAUGUU AACAUUUGGUUUCUGCCGCCACUGG 
Ptk2b A GGGAUAUUGCUGUCCGGAATT 
 
UUCCGGACAGCAAUAUCCCTG 
Ptk2b B AGCUGGGACACUACCUGGAACGAAA UUUCGUUCCAGGUAGUGUCCCAGCU 
 
 
Transfection of 293T cells 
 
Transfection of 293T cells was performed to study protein signaling and to produce retroviral vectors. 
Therefore the cells were seeded out at a density of 0,6 x 106 cells in a 6-well plate and the transfection mix 
was added when the cell reached 50-70% confluency. The transfection mix contained 400 µl serum-free 
medium, 2 µg DNA and 4 µl Turbofect transfection reagent (Fermentas). After 20 minutes of incubation, the 
transfection mix was added drop wise to the medium of the 293T cells. The cells or viral vectors were 
harvested 48 hours after transfection. 
 
 
Retroviral transduction 
 
For a stable expression of our transgenes in Ba/F3 and MOHITO cells, we first cloned our genes of interest 
into Murine Stem Cell Virus (MSCV) retroviral expression vectors containing a GFP or puromycin selection 
marker. The 293T cells secrete the viral vectors in their medium after co-transfection of the retroviral vectors 
and an ecotropic packaging vector. The viral supernatant is harvested and filtered with acrodisc 0,45 µm 
filters (VWR) 48 hours after transfection. Transduction of the mouse cells with these vectors leads to a stable 
integration of the vector in the genome. For the transduction of Ba/F3 cells, 1 ml of viral supernatant was 
added to 1 x 106 cells in 1 ml of growth medium supplemented with 8 µg/ml Polybrene (Sigma-Aldrich) and 
IL-3 (Peprotech Inc.). After 24 hours, the cells were washed and the percentage GFP+ cells was measured 
by flow cytometry or cells containing the puromycin resistance gene were selected by adding 1 µg/ml 
puromycin to the medium. For the transduction of MOHITO cells, non-tissue treated 6-well plates were 
coated with RetroNectin (TAKARA Bio Inc.) and the retroviral supernatant was bound to the plate surface by 
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centrifugation (1000g, 30°C, 2 hours). After virus binding and removal of the supernatant, 1 x 106 MOHITO 
cells in 2 ml growth medium supplemented with 5 ng/ml IL-2 and 10 ng/ml IL-7 (Peprotech Inc.) were added 
to the plate followed by a spinoculation step (2000g, 30°C, 1 hour) to increase the contact between virus and 
cell. After recovery, the cells were removed from the RetroNectin plates and the GFP percentage was 
determined or puromycin selection was performed as described above. 
 
 
Electroporation and siRNA-mediated knockdown 
 
Cells were resuspended in 400 µl of serum-free growth medium, which contained 300-400 nM siRNA, and 
transferred to 4-mm cuvettes (Bio-Rad). The amount of cells, the concentration of the siRNA and the 
electroporation parameters differ for each specific cell line used (Table 3). The electroporated cells were 
transferred to 12-well plates containing 2ml pre-warmed growth medium. Knockdown efficiency is analyzed 
through western blotting or qRT-PCR. Growth reduction was analyzed by measuring the amount of viable 
cells 1 hour and 48 hours after electroporation using the GUAVA flow cytometer (Millipore). The siRNAs 
targeting the gene of interest and their negative controls were purchased from IDT and Invitrogen. 
 
Table 3. Electroporation parameters for cell lines 
Cell line Amount of cells Amount of siRNA Electroporation parameters 
MOHITO 1,5 x 106 300 nM Exponential decay, 350 V, 500 µF 
Ba/F3 1 x 106 400 nM Exponential decay, 300 V, 950 µF 
 
 
Western blotting 
 
Cells were lysed in cold lysis buffer (Cell Signaling Technology – Bioké) supplemented with protease 
inhibitors (cOmplete Protease Inhibitor Cocktail tablets). Protein concentrations were determined using the 
Bio-Rad protein assay, which measured the sample absorbance at 595nm. Next the proteins were 
denaturated and reduced on 70°C for 10 minutes in NuPAGE LDS sample buffer and NuPAGE Reducing 
agent (Life Technologies). The proteins were separated on NuPAGE NOVEX Bis-Tris 4-12% gels 
(Invitrogen) and transferred to PVDF membranes (GE Healthcare). Subsequent western blot analysis was 
performed using primary antibodies (Table 4) and the secondary antibodies sheep anti-mouse IgG-HRP, 
donkey anti-rabbit IgG-HRP (GE Healthcare) and donkey anti-goat IgG-HRP (Santa Cruz 
Biotechnology/SCBT). For the signal detection, the membranes were treated for weak signals with the 
Amersham ECL Prime Western Blotting detection reagent (GE Healthcare) and for strong signals with the 
Western Lightning Plus ECL (Perkin Elmer) and the signals were visualized on the Image Quant LAS 4000 
mini imager (Fujifilm). 
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Table 4. Primary antibodies 
Antibody Ref. Number Company 
b-actin A1978 Sigma-Aldrich 
Phospho-CBL #8869 Cell Signaling Technology 
ERK1/2 Sc-93 Santa Cruz Biotechnologies 
Phospho-ERK1/2 (Thr202/Tyr204) #4377 Cell Signaling Technology 
JAK1 05-1154 Millipore 
Phospho-JAK1 (Tyr1022/1023) sc-16773R Santa Cruz Biotechnologies 
LCK sc-13 Santa Cruz Biotechnologies 
Phospho-LCK (Tyr394) SAB4300118 Sigma-Aldrich 
Phospho-LCK (Tyr505) #2751 Cell Signaling Technology 
MEK1/2 #9126 Cell Signaling Technology 
Phospho-MEK1/2 (Ser217/221) #9154 Cell Signaling Technology 
PDGFRα sc-338 Santa Cruz Biotechnologies 
Phospho-PDGFRα sc-12911-R Santa Cruz Biotechnologies 
PTEN sc-7974 Santa Cruz Biotechnologies 
PTPRD sc-10867 Santa Cruz Biotechnologies 
PTK2B #3480 Cell Signaling Technology 
Phospho-PYK2 (Tyr402) #3291 Cell Signaling Technology 
Phospho-SRC family #2101 Cell Signaling Technology 
STAT1 #9172 Cell Signaling Technology 
Phospho-STAT1 (Tyr701) #9167 Cell Signaling Technology 
STAT3 #4904 Cell Signaling Technology 
Phospho-STAT3 (Tyr705) #9138 Cell Signaling Technology 
STAT5 #9358 Cell Signaling Technology 
Phospho-STAT5 (Tyr694) #9359 Cell Signaling Technology 
 
 
Cytokine stimulation experiments 
 
Cytokine dependent cell lines were washed thrice with PBS (Life Technologies) to remove the cytokines and 
starved for 3 hours in their growth medium without cytokines. For each condition 4 x 106 cells were 
stimulated with 5 ng/µl IL-2 and 10 ng/µl IL-7 during 10-20 minutes. In some conditions 100 nM final 
concentration of the SRC inhibitors, AZD0530 (Selleckchem) and dasatinib (Selleckchem), were added. As a 
negative control for the used inhibitors, the addition of dimethyl sulfoxide (DMSO) was used. 
 
 
Inhibitor assay 
 
To obtain dose-response curves, MOHITO cells were seeded in five-fold in 96-well plates at a concentration 
of 3 x 105 cells in a total volume of 100 µl and JAK inhibitors, ruxolitinib (Axon Medchem) and tofacitinib 
(Selleckchem), or SRC inhibitors, AZD0530 (Selleckchem) and dasatinib (Selleckchem), were added with 
increasing concentrations. As a negative control, the addition of DMSO was used. The amount of viable cells 
was measured after seeding and after an incubation time of 24 and 48 hours by measuring the luminescence 
on a Victor X4 plate reader (Perkin-Elmer) after adding ATPlite (Perkin-Elmer). 
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Migration assay 
 
For the migration assay, ThinCerts with a pore size of 8 µm (Greiner Bio-One) were placed in wells of a  
24-well plate. To the ThinCerts, 2 x 105 MOHITO cells resuspended in 100 µl growth medium, containing 5% 
FBS, 5 ng/ml IL-2 and 10 ng/ml IL-7, was added. To the wells, 600 µl of 20% FBS growth medium 
supplemented with 5 ng/ml IL-2 and 10 ng/ml IL-7 was added. A final concentration of 100 nM of AZD0530 
or dasatinib was added to the medium in the insert and the well. To explore how many cells after an 
incubation time of 6 hours migrated through the membrane of ThinCert to the well, the amount of viable cells 
in the well and in the ThinCert was measured with the GUAVA flow cytometry. The percentage cell invasion 
was calculated according to the calculation: cell invasion (in %) = N lower/(N lower + N upper) x 100 
 
 
Phospho–proteomics 
 
To identify the signaling pathways controlled by PTPN2, we performed the Stable Isotope Labeling by Amino 
Acids in Cell culture (SILAC) phospho-proteomics method. Untransduced MOHITO cells were grown in light 
RPMI SILAC labeled media containing L-Lysine and L-Arginine amino acids. MOHITO cells with knockdown 
of PTPN2 were grown in heavy RPMI SILAC labeled media containing [U-13C6]-L-Lysine and Arg10  
L-Arginine heavy labeled amino acids. After 6 doubling times, 100 x 106 cells of each culture were lysed with 
a freshly made cell lysis buffer, containing 50 mM Tris (pH 7,5), 150 mM NaCl, 1% NP-40, 0,25% Na, 
deoxycholate, protease inhibitor cocktail, 1mM Na3VO4, 5 mM β-glycerophosphate and 5 mM NaF. Next, the 
cell lysates of both cultures were mixed in a 1:1 ratio. To isolate the tyrosine-phosphorylated proteins from 
the cell lysate immunoprecipitation was performed with Dynabeads Protein G (Life Technologies) and the 
4G10 (Upstate) and PY100 (Cell Signaling Technologies) anti-phospho-tyrosine antibodies. After 
immunoprecipitation the proteins in the cell lysates were separated by electrophoresis on a NuPAGE 
NOVEX Bis-Tris 4-12% gel. After visualization of the separated proteins with coomassie staining, the gel was 
cut in smaller pieces for in-gel digestion, which was performed as described previously132. The fragmented 
peptides were next analyzed on the LTQ Orbitrap mass spectrometry by the group of prof. Dr. Blagoy in 
Denmark. 
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CHAPTER IV - RESULTS 
 
1 Development of a siRNA and shRNA screening system based on a kinase fusion protein 
 
The obtained results described in this part have been published as: 
Pieraets S, Cox L, Gielen O and Cools J. Development of a siRNA and shRNA screening system based on 
a kinase fusion protein. RNA (2012), 18:1296-1306. 
 
 
ABSTRACT 
 
RNA interference (RNAi) is one of the processes in the cell that regulates mRNA expression levels. RNAi 
can be exploited to experimentally knockdown the expression of one or more genes in cell lines or even in 
cells in vivo and became also an interesting tool to develop new therapeutic approaches. One of the major 
challenges of using RNAi is selecting effective shRNAs or siRNAs that sufficiently downregulate the 
expression of the target gene. Here, we describe a system to select functional shRNAs or siRNAs that 
makes use of the leukemia cell line Ba/F3 that is dependent on the expression of a mutant form of the 
PDGFRα kinase for its proliferation and survival. The basis of this system is the generation of an expression 
construct where part of the open reading frame of the gene of interest is linked to the mutant PDGFRα. 
Thus, shRNAs or siRNAs that effectively target the gene of interest also result in a reduction of the 
expression of the mutant PDGFRα protein, which can be detected by a reduction of the proliferation of the 
cells. We demonstrate that this validation system can be used for the selection of effective siRNAs as well as 
shRNAs. Unlike other systems, the system described here is not dependent on obtaining high transduction 
efficiencies, and non-specific effects of the siRNAs or shRNAs can be detected by comparing the effects in 
the presence or absence of the growth factor interleukin-3. 
 
 
INTRODUCTION 
 
RNA interference (RNAi) is the process of gene silencing that occurs in a sequence specific manner at the 
level of the mRNA133. The basic process of RNAi can be divided into three steps. Initially, the ribonuclease III 
enzyme Dicer cleaves a long double stranded RNA, which is expressed or introduced into the cell, into small 
RNAs (20-30 nucleotides). Secondly, one strand of the small RNA, the guided strand, is loaded onto the 
RNA-induced silencing complex (RISC), while the other, the passenger strand, is degraded. Finally, the 
guided strand binds the target mRNA, which results in the degradation of the mRNA. Human cells express 
hundreds of non-coding RNAs that are processed in the cell to short RNAs that enter the RNAi pathway and 
are important for gene expression regulation134-136. Synthesized double stranded short interfering RNAs 
(siRNAs) introduced into the cell or short hairpin RNAs (shRNAs) or miRNA-based shRNAs (shRNAmirs) 
expressed in the cell use the cellular mechanism of RNAi to interfere with the expression of a specific gene 
and in this way create a cell that lacks sufficient expression levels of that gene133-135,137. 
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In the lab RNAi is used as a research tool in the siRNA and shRNA/shRNAmir mode. Such siRNAs are  
∼21-25 nucleotides long and are introduced artificially by means of transfection or electroporation. The 
shRNAs and shRNAmirs are typically incorporated in expression vectors such as plasmids or 
retroviral/lentiviral vectors, through which the shRNAs or shRNAmirs are stably integrated in the host 
genome. Those synthesized small RNA molecules use the endogenous RNAi pathway in eukaryotic cells for 
the degradation of their target mRNA133-135,137,138. 
 
Despite the general use of RNAi in research, there are still a number of limitations and difficulties associated 
with this technology. First of all, delivery of siRNAs to cells in vitro and even more in vivo remains a 
bottleneck for the widespread use of RNAi. Second, despite the specificity due to the sequence of the 
siRNAs or shRNAs, off-target effects are present and may cause unwanted and difficult to control side 
effects. Third, the selection of siRNA or shRNA sequences that are effective in downregulating the 
expression of the target genes remain difficult138-142. Although design algorithms have improved in the last 
years, there are still difficulties in identifying effective and specific siRNAs and shRNAs. Therefore, it is still 
required to experimentally validate every siRNA or shRNA that is used, and for a specific gene, 10 or more 
sequences may need to be tested to identify one RNAi molecule that is causing sufficient knockdown143-145. 
 
To assist in the identification of functional siRNAs or shRNAs, a number of experimental validation systems 
have been developed. Those validation systems consist of a reporter assay where a target gene is fused to 
a fluorescent or enzymatic reporter. In these systems, expression of functional shRNAs or siRNAs results in 
a decrease of the reporter signal, and thus loss of fluorescent or enzymatic activity is a measure for the 
knockdown efficiency of the siRNAs or shRNAs146-153. 
 
In this work, we describe the development of a protein-kinase fusion system in Ba/F3 cells that is based on a 
proliferation read-out to test the knockdown efficiency of RNAi molecules. 
 
 
RESULTS 
 
Development of the Ba/F3 validation system 
 
In order to evaluate the silencing capacity of selected shRNAs or siRNAs in a medium- to high-throughput 
system, we developed a cell-based system in which shRNA/siRNA molecules that efficiently knockdown the 
expression of a given gene would inhibit cell proliferation. In this way, the silencing effect can be read from 
the effect on cell proliferation, as is also done in cell-based drug screens (Fig. 13). For this, we used the 
interleukin-3 (IL-3) dependent pro-B-cell line (Ba/F3). These Ba/F3 cells are dependent on IL-3 for their 
proliferation and survival, but can also become dependent on oncogenic tyrosine kinases such as activated 
ABL, FLT3, PDGFRα, and many other kinases154,155. For our system, we used a truncated form of PDGFRα 
(named “tPDGFRα”), known to be constitutively activated and to stimulate the proliferation and survival of 
Ba/F3 cells in the absence of IL-330-32,155. 
 
Results 
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Schematic overview of the use of the validation system for selecting functional shRNAs or siRNAs (A) Ba/F3 cells 
expressing tPDGFRα or a fusion of tPDGFRα with a gene of interest can grow in the absence of the growth factor IL-3. These Ba/F3 
cells are completely dependent on the expression of the mRNA containing the tPDGFRα open reading frame. The gene of interest is 
placed on the same mRNA, either upstream or downstream of the tPDGFRα. The asterix indicates the presence of a stop codon. (B) 
Transduction of the Ba/F3 cells with shRNAs (co-expressing GFP) that effectively downregulate the gene of interest and thus prevent 
expression of the tPDGFRα, will result in a decrease of the number of GFP positive cells in the culture. (B’) Electroporation of Ba/F3 
cells with siRNAs that effectively downregulate the gene of interest and thus prevent expression of the tPDGFRα, will inhibit the 
proliferation of the cells. 
 
Based on our previous experiences with the Ba/F3 cell system, we reasoned that this cell system would be a 
good screening system to select efficient siRNA or shRNA sequences. Ba/F3 cells transformed by tPDGFRα 
have a short doubling time and are absolutely dependent on the activated kinase for their proliferation and 
survival. A siRNA targeting tPDGFRα can be used as a positive control in the screens, and IL-3 can be 
added to the cells to make them independent of tPDGFRα in order to distinguish between specific and toxic 
off-target effects of the siRNAs or shRNAs. Finally, the tPDGFRα can be fused to additional sequences 
without affecting its function32. In this way, the gene of interest (the gene that one wants to target) can be put 
on the same transcript as tPDGFRα (Fig. 13, 14A). 
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Three different variants of the vector were generated: variant 1 with the target gene upstream of tPDGFRα, 
generating a fusion protein between the coding sequence of the target gene and tPDGFRα; variant 2 with 
the target gene downstream of tPDGFRα with a fusion between tPDGFRα and the coding sequence of the 
target gene; and variant 3 with the target gene downstream of tPDGFRα on the same RNA, but without 
generating a fusion protein (Fig. 14A). Thus, the first two variants result in the expression of a fusion protein 
of tPDGFRα with the protein of interest (or a part of the protein of interest), while in the third version the 
target gene is present as the 3’ untranslated region (UTR) of tPDGFRα (Fig. 13, 14A). To keep the ATG 
context the same for each construct a MYC-tag was cloned in front of each transcript. In that way we reduce 
variations in transcription among the different construct to a minimum. 
 
 
Figure 14. Expression of all constructs containing the tPDGFRα  in Ba/F3 cells results in IL-3 independent growth (A) Schematic 
representation of the different constructs: myc-Pten-tPDGFRα, myc-p16-tPDGFRα, myc-tPDGFRα-Pten and  
myc-tPDGFRα-p16, myc-tPDGFRα*-Pten and myc-tPDGFRα*-p16. The target genes Pten and p16 were cloned upstream of the 
tPDGFRα, downstream and downstream with a stop codon (*) in between. (B) Ba/F3 cells transduced with the tPDGFRα constructs 
grow in the absence of IL-3. Untransduced Ba/F3 cell do not survive without IL-3. Mean growth ± SEM was recorded in triplicate for 3 
days. (C) All transformed Ba/F3 cells showed expression (upper panel) and phosphorylation (central panel) of the tPDGFRα. 
Expression of β-actin (lowest panel) is used as control for the loading. (D) Compared to the untransformed cells, growth of the 
transformed Ba/F3 cells was reduced when treated with 100 nM of the PDGFRα kinase inhibitor imatinib. Mean growth ± SEM was 
recorded in triplicate on day 0 and 2. (E) The transformed Ba/F3 cells became again dependent on IL-3 for their cell growth after 
electroporation with an effective siRNA targeting PDGFRα. As control, all cell lines were electroporated with a scrambled siRNA. Mean 
growth ± SEM was recorded in triplicate on day 0 and 2. Data of the scrambled siRNA are set to 100% and data of the tested siRNAs 
are relative to the scrambled siRNA. 
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Selection of shRNAs targeting p16 and Pten using the Ba/F3 system 
 
In order to test the Ba/F3 system, we designed shRNAs targeting mouse Pten and mouse Cdkn2a (p16), and 
tested if the Ba/F3 system could be used to select the most potent shRNA. We generated tPDGFRα 
constructs containing the coding sequences of Cdkn2a (p16) and Pten (Fig. 14A). These constructs were 
retroviral transduced in Ba/F3 cells. As such, six different Ba/F3 cell lines were generated to test the system. 
All six newly generated Ba/F3 cell lines could grow in the absence of IL-3 at the same proliferation rate as 
the control cells expressing only the truncated form of PDGFRα (Fig. 14B). Western blot analysis revealed 
auto-phosphorylation of all tPDGFRα fusion proteins in these different cell lines, indicating that all cell lines 
expressed activated PDGFRα as expected (Fig. 14C). In addition, the growth of all cell lines was inhibited by 
the PDGFRα kinase inhibitor imatinib, further confirming that the cell lines were all strictly dependent on the 
expression of the activated PDGFRα (Fig. 14D). In another experiment we showed that after electroporation 
with an effective siRNA against tPDGFRα those cell lines were again dependent on IL-3 for their cell growth 
(Fig. 14E). 
 
To test the potency of the different retroviral shRNA vectors, we transduced the variant Ba/F3 cells with 
these retroviral vectors and followed the effect on the proliferation of the transduced cells. Transduction 
efficiencies between 40 and 70% were obtained. Since the shRNA vectors also express green fluorescent 
protein (GFP), we could identify shRNA-expressing cells using flow cytometry, which allowed us to trace the 
fate of the transduced cells over time. If the percentage GFP positive cells decreased over time, this was 
indicative of effective knockdown of the target RNA, since the target RNA is on the same RNA as tPDGFRα, 
which is required for the proliferation of the cells (Fig. 13). 
 
In a first set of experiments we used the Ba/F3 cell lines with the open reading frames of p16 or Pten 
positioned upstream of tPDGFRα and could demonstrate a clear distinction between effective and  
non-effective shRNAs. In the cells expressing p16-tPDGFRα the strongest decrease of GFP positive cells 
was obtained with shRNA-p16-1. ShRNA-p16-3 was less efficient and no effect was observed for  
shRNA-p16-2 at the endpoint of the experiment, 11 days after transduction. No significant change in the 
GFP positive population was observed in the control cells that expressed tPDGFRα or the cells containing 
the Pten-tPDGFRα fusion (Fig. 15A).  
 
When targeting the cells expressing Pten-tPDGFRα, all three shRNAs targeting Pten were found to be 
effective, with the strongest effect observed for shRNA-Pten-4. To rule out that the effects observed on the 
proliferation of the Ba/F3 cells was due to more general toxic effects, we also tested the Pten shRNAs in 
parental Ba/F3 cells and Ba/F3 cells expressing p16-tPDGFRα. The different Pten shRNAs had no effect on 
the control cells or on the cells containing the p16-tPDGFRα fusion confirming that the observed effects were 
specific (Fig. 15A). 
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Figure 15. Screening of shRNAs using Pten-tPDGFRα  and p16-tPDGFRα  transformed Ba/F3 cells (A) Effective shRNAs lead to a 
decrease in the relative amount of GFP positive cells in contrast to non-effective shRNAs. Mean relative amount of GFP positive cells ± 
SEM was recorded in triplicate on day 2, 4, 7, 9 and 11. All values on day 2 are set to 100% and all other values are relative to day 2. 
(B) The proliferation of Ba/F3 cells expressing the p16-tPDGFRα or Pten-tPDGFRα fusion proteins were inhibited after expression of 
shRNA-p16-1 or shRNA-Pten-4, and this inhibition could be rescued by the addition of IL-3. Mean relative amount of GFP positive cells 
± SEM was recorded in triplicate on day 2, 4, 7, 9 and 11. All values on day 2 are set to 100% and all other values are relative to day 2. 
(C) Downregulation of Pten-tPDGFRα and p16-tPDGFRα protein expression in transformed Ba/F3 cells transduced with shRNAs 
against p16 and Pten. Cell lysates were obtained 4 days after transduction. 
 
 
Toxic off-target effects of a shRNA can be identified by simply adding IL-3 to the transformed cells, which 
makes the cells independent from the tPDGFRα protein by stimulating their proliferation and survival through 
the IL-3 receptor. Specific shRNAs that target p16 or Pten in the tPDGFRα transcripts should result in 
inhibition of cell proliferation, and this negative effect on proliferation should be rescued by the addition of  
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IL-3. Indeed, we showed that the cell lines, expressing the p16-tPDGFRα or Pten-tPDGFRα fusion proteins, 
could proliferate in the presence of IL-3 after transduction with the effective shRNA-p16-1 or shRNA-Pten-4, 
but not in the absence of IL-3 (Fig. 15B). These data confirm that the effects we observed of the shRNAs in 
the absence of IL-3 are not due to a nonspecific effect of the shRNAs. 
 
The data of the proliferation assay were confirmed by protein expression analysis in transformed Ba/F3 cells 
containing p16-tPDGFRα transduced with the shRNAs targeting p16, and similarly in cells containing  
Pten-tPDGFRα transduced with shRNAs targeting Pten. As expected, the effective shRNA-p16-1 and -3 
resulted in a significant decrease of the protein expression of p16-tPDGFRα, while there was no 
downregulation of p16-tPDGFRα protein levels by shRNA-p16-2 (Fig. 15C). Furthermore, the strongest 
downregulation of the Pten-tPDGFRα fusion gene was observed for shRNA-Pten-4. To a lesser extend 
shRNA-Pten-2 and -3 also resulted in decreased protein expression of Pten-tPDGFRα. There was no 
knockdown in the control experiments where Ba/F3 cells with p16-tPDGFRα were transduced with Pten 
shRNAs or where Ba/F3 cells with Pten-tPDGFRα were transduced with p16 shRNAs, indicating the 
specificity of the system (Fig. 15C). 
 
For the experiments described above, we only used the constructs in which the gene of interest (p16 or 
Pten) was cloned upstream of tPDGFRα, generating p16-tPDGFRα or Pten-tPDGFRα fusion proteins. Next, 
we determined if the system was also functioning in cases where the gene of interest was cloned 
downstream of tPDGFRα, either as fusion protein or downstream from the stop codon of tPDGFRα (thus in 
the 3’ UTR of tPDGFRα). Our results show that the position of the target gene indeed matters. Although  
shRNA-p16-1 could potently decrease the proliferation of Ba/F3 cells expressing p16-tPDGFRα, much less 
effect was observed with the shRNA in cells expressing tPDGFRα-p16 or tPDGFRα*-p16. Similarly,  
shRNA-Pten-4 resulted in substantially lower decrease in the amount of GFP positive cells in experiments 
with Pten-tPDGFRα compared to tPDGFRα-Pten or tPDGFRα*-Pten (Fig. 16A). The same results were 
observed on protein level when the genes of interest were placed in front of tPDGFRα. After transduction 
with shRNA-p16-1 reduction in p16-tPDGFRα expression level was more pronounced compared to 
tPDGFRα-p16 or tPDGFRα*-p16. No knockdown of the control constructs containing Pten was observed 
with shRNAs targeting p16. Also, the protein level of Pten-tPDGFRα was more reduced after shRNA-Pten-4 
transduction compared to tPDGFRα-Pten or tPDGFRα*-Pten. There was no knockdown of the control 
constructs containing p16 with shRNAs targeting Pten (Fig. 16B). Similar results were obtained for the other 
shRNAs (data not shown). These data demonstrate that for the proliferation read-out, the constructs in which 
the gene of interest are positioned at the 5’ end of the mRNA, upstream of tPDGFRα, are to be preferred. 
These results also confirm that we do not obtain similar knockdown effects for the three different variants of 
the system, and thus that knockdown efficiency is dependent on the position of the target sequence in the 
mRNA. 
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Figure 16. Screening of shRNAs directed against Pten and p16 results in different outcomes according to the position of the 
gene of interest in the tPDGFRα  constructs (A) Effective shRNAs result in a decrease of the relative amount of GFP positive cells 
when Pten and p16 are placed upstream of the tPDGFRα. A less clear effect is observed when Pten and p16 are downstream of the 
tPDGFRα. Mean relative amount of GFP positive cells ± SEM was recorded in triplicate on day 2, 4, 7, 9 and 11. All data on day 2 are 
set to 100%, and all other data are relative to day 2. (B) Downregulation of tPDGFRα and tPDGFRα fusion proteins in the transformed 
Ba/F3 cells transduced with shRNA-p16-1 or shRNA-Pten-4. Cell lysates were obtained 4 days after transduction. 
 
 
Selection of siRNAs targeting p16 and Pten using the Ba/F3 validation system 
 
In addition to testing of shRNAs, we also applied our validation system for the selection of effective siRNAs 
by electroporation of the Ba/F3 cells (Fig. 13B’). We electroporated the Ba/F3 cells expressing  
p16-tPDGFRα or Pten-tPDGFRα with 10 siRNAs directed against p16 and 10 siRNAs directed against Pten, 
respectively. Two days after electroporation, we measured the growth of the cells, which revealed major 
differences between the different siRNAs (Fig. 17A). Four of these siRNAs were tested in more detail  
(Fig. 17A, indicated in orange) and effects were confirmed in a second experiment (Fig. 17B). The growth 
reduction was the highest for siRNA-p16-3 and siRNA-Pten-9 respectively. SiRNA-p16-4, siRNA-p16-5, 
siRNA-Pten-1 and siRNA-Pten-2 were less effective in reducing the growth of the cells. The non-effective 
siRNA-p16-D and siRNA-Pten-A were not able to reduce the growth in the transformed Ba/F3 cells 
containing the p16-tPDGFRα or Pten-tPDGFRα respectively (Fig. 17B). As also observed for the shRNAs, 
the effect of the siRNAs on cell proliferation was less pronounced when p16 and Pten were placed 
downstream of the tPDGFRα (data not shown).  
 
As shown for the shRNA experiments, cell lines electroporated with siRNAs can be grown in the presence of 
IL-3 to distinguish between specific and toxic effects. The cell lines expressing p16-tPDGFRα or  
Pten-tPDGFRα survived after electroporation with an effective siRNA against p16 or Pten when IL-3 was 
added (Fig. 17C). These data confirm that the siRNAs produce the inhibitory effect on proliferation of the 
cells specifically through the knockdown of the p16-tPDGFRα or Pten-tPDGFRα transcripts, and not due to 
non-specific knockdown of critical genes needed for proliferation or survival. 
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In general, the knockdown effect on protein expression (Fig. 17D) correlated well with the effect on cell 
proliferation (Fig. 17B). Indeed, clear downregulation of expression of the p16-tPDGFRα or Pten-tPDGFRα 
fusion proteins was observed when the cell lines were electroporated with the siRNAs that had a clear effect 
on the proliferation of the cells, while less or no knockdown was observed for siRNAs not having much effect 
on the proliferation (Fig. 17B and D). These data confirm the correlation between effects on protein 
expression and effects on cell proliferation in the Ba/F3 system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Screening and validation of siRNAs (A) Ten siRNAs directed against Pten and p16 were screened in the p16-tPDGFRα 
and the Pten-tPDGFRα transformed Ba/F3 cells respectively. The siRNAs indicated in orange were confirmed in a second experiment 
(panel B). (B) Effective siRNAs result in reduced growth of p16-tPDGFRα and Pten-tPDGFRα transduced Ba/F3 cells. Mean growth ± 
SEM was recorded in five-fold on day 0 and 2. Data of the scrambled siRNA are set to 100%, data of the tested siRNAs are relative to 
the scrambled siRNA. (C) The proliferation of Ba/F3 cells expressing the fusion protein p16-tPDGFRα or Pten-tPDGFRα was inhibited 
after electroporation with the effective siRNA-p16-3 or siRNA-Pten-1, respectively, and this inhibition could be rescued by the addition of 
IL-3. As control, all cell lines were electroporated with a scrambled siRNA. Mean growth ± SEM was recorded in triplicate on day 0 and 
2. Data of the scrambled siRNA are set to 100% and the data of the tested siRNAs are relative to the scrambled siRNA. (D) Effective 
siRNA gave a reduction in the protein expression of p16-tPDGFRα and Pten-tPDGFRα. 
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Correlation of the knockdown efficiency in the Ba/F3 cell system with knockdown of endogenous 
Pten or p16 expression in mouse cell lines 
 
Previous experiments demonstrated the potential use of the Ba/F3 system to screen for functional siRNAs or 
shRNAs, but did not address the correlation between the results in the Ba/F3 cell system and the effects on 
the normal endogenous transcripts of Pten or Cdkn2a. To investigate if the results of the Ba/F3 system 
reflect the knockdown efficiencies obtained on endogenous transcripts, we next performed experiments with 
parental Ba/F3 cells and MOHITO cells156. We determined whether the effective shRNAs and siRNAs, 
validated in the system, were also able to downregulate endogenous Pten transcripts in Ba/F3 cells. Due to 
the absence of endogenous p16 expression in Ba/F3 cells we used endogenous Cdkn2a (p16) transcripts in 
MOHITO cells to validate the p16 RNAi molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Downregulation of endogenous Pten and p16 in Ba/F3 cells and in MOHITO cells (A) Downregulation of endogenous 
Pten expression in Ba/F3 cells by shRNAs (left panel) and by siRNAs (right panel). The control shRNA mentioned in the left panel is  
shRNA-p16-1. (B) Reduction in endogenous p16 transcripts in MOHITO cells by shRNAs (left panel) and by siRNAs (right panel). The 
control shRNA in the left panel is shRNA-Pten-4. Cell lysates and RNA of cells transduced with shRNAs were obtained 4 days after 
transduction and cell lysates and RNA of cells electroporated with siRNAs were obtained 2 days after electroporation. 
 
 
Parental Ba/F3 cells were transduced with the shRNAs targeting Pten, and knockdown of Pten transcripts 
was measured by the detection of Pten protein expression. The three shRNAs produced strong knockdown 
of Pten (Fig. 18A, left panel), which correlated well with effects observed in the Ba/F3 validation system  
(Fig. 15), where also all three shRNAs showed strong effects with the shRNA-Pten-4 being the most potent. 
Decrease in the endogenous Pten expression was also observed when Ba/F3 cells were electroporated with 
the siRNAs targeting Pten. Compared to the scrambled siRNA, the decrease in expression was minimal 
when electroporated with the siRNA-Pten-A, and a strong knockdown was observed with siRNA-Pten-1, 
siRNA-Pten-2 and siRNA-Pten-9 (Fig. 18A, right panel). These data recapitulated well the data observed 
with the Pten-tPDGFRα expressing Ba/F3 cells (Fig. 17). 
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Similarly, also for the p16 shRNAs, a good correlation was observed between the knockdown of the p16 
transcript in MOHITO cells (Fig. 18B, left panel) and the Ba/F3 validation system experiments (Fig. 15) in 
which shRNA-p16-1 was indicated as the most efficient shRNA. Finally, knockdown efficiencies of the p16 
siRNAs were tested on endogenous p16 expression in the MOHITO cell line. We observed the best 
knockdown for siRNA-p16-3 (Fig. 18B, right panel), as also observed in the Ba/F3 validation system  
(Fig. 17), while the knockdowns for the other siRNAs were slightly different from those observed in the 
validation system (Fig. 18B, right panel). Thus overall, the knockdown effects observed for the endogenous 
transcripts correlated very well to the knockdown measured with the Ba/F3 validation system. 
 
 
DISCUSSION 
 
Since the discovery of RNAi, gene silencing has been used with increasing interest in both research and 
therapeutic applications. Over the last years, many algorithms for shRNA and siRNA design have been 
developed, all based on empirical rules. While these algorithms assist in the selection of RNAi molecules, 
none of the currently available algorithms can predict the efficiency of siRNAs and shRNAs with high 
accuracy143,144. Here we describe the development and evaluation of a cell-based validation system to 
complement classical design algorithms to make better choices for effective gene silencing by means of 
RNAi.  
 
The system we describe here is based on the transforming properties of a truncated form of the PDGFRα 
kinase (tPDGFRα) in Ba/F3 cells. Ba/F3 cells expressing tPDGFRα proliferate fast (doubling time less than 
24 hours) and are completely dependent on the presence of tPDGFRα for their proliferation and survival. We 
hypothesized that by putting the gene of interest on the same transcript as tPDGFRα, we could generate a 
sensor for efficiency of knockdown of the gene of interest. Effective shRNAs and siRNAs, introduced by 
transduction or electroporation respectively, target the gene of interest that results in downregulation of the 
tPDGFRα fusion protein. Loss of tPDGFRα will block proliferation and survival of the Ba/F3 cells, which is an 
easy read-out to measure in these rapidly proliferating cells. 
 
Our results show that this is indeed possible. We tested the system by cloning the coding sequences of 
mouse Cdkn2a (p16) or mouse Pten on the tPDGFRα transcript (Fig. 14A). Combining two RNA fragments 
in a transcript may alter the RNA secondary structure, which can affect binding of the RNAi molecules to the 
target RNA sequence. For this reason we tested three different variants for each gene of interest. We 
generated (1) p16-tPDGFRα or Pten-tPDGFRα fusion transcripts that encode p16-tPDGFRα or  
Pten-tPDGFRα fusion proteins, (2) tPDGFRα-p16 or tPDGFRα-Pten fusion transcripts that encode 
tPDGFRα-p16 or tPDGFRα-Pten fusion proteins, or (3) tPDGFRα*-p16 or tPDGFRα*-Pten fusion transcripts 
that will express only the tPDGFRα protein, since a stop codon is present at the end of the coding sequence 
of tPDGFRα and the p16 or Pten sequences are thus present in the 3’ UTR of this transcript. The 
documented knockdown effects on protein level and on proliferation of the cells were much more 
pronounced in the first variant with the p16-tPDGFRα and Pten-tPDGFRα fusion proteins (Fig. 16). This 
could be the consequence of structural characteristics of the fusion RNAs and could potentially also be 
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explained by an incomplete degradation of the transcripts when the RNAi molecules are targeting the 3’ 
region of the transcript. In contrast, when the target gene is cloned at the 5' end, a single cut of the transcript 
will directly lead to a disconnection between the ATG start codon and the PDGFRα reading frame and a 
direct loss of the fusion protein. We therefore recommend using the set up where the gene of interest is 
cloned upstream of the oncogenic kinase for future experiments. 
 
We realize that our screening method is an artificial system and therefore has a few disadvantages. It is 
possible that RNAi molecules with a good knockdown efficiency in the system will not reach this level of 
knockdown when targeting the endogenous transcripts. Nevertheless, in this study we observed a good 
correlation between the knockdown efficiency of p16 and Pten obtained in the screening system and the 
knockdown of endogenous p16 and Pten in mouse cell lines. 
 
In this study we showed that our validation system is a reliable system that is able to identify efficient 
shRNAs and siRNAs. From three tested shRNAs directed against p16, only one shRNA was identified as a 
shRNA with strong RNAi effect, and this shRNA was confirmed to function well to downregulate the 
expression of the endogenous p16 transcript in MOHITO cells. Similarly, a good correlation between the 
results in the Ba/F3 validation system and knockdown effects on the endogenous gene was observed for 
Pten as well. The validation system detected clear differences between different siRNAs or shRNAs, and a 
strong correlation was documented with effects on the endogenous transcripts. These data support the 
Ba/F3 validation system as a potent and easy to use system to select siRNAs or shRNAs with a good 
knockdown effect. 
 
Our system has a few important differences compared to experimental validation systems described in the 
past. In those systems a reporter assay is used where a target gene is fused to a fluorescent or enzymatic 
reporter gene, like EGFP or luciferase respectively. Reduction in the fluorescent or enzymatic activity is 
observed when effective shRNAs or siRNAs target the gene of interest147-153,157. The read-out of our system 
is the reduction in cell growth due to downregulation of the tPDGFRα protein kinase fused to the target gene. 
Looking at the direct cellular effects might have some advantages, since protein levels in artificial systems 
may not always correlate with the cellular effects.  
 
A major challenge for many validation systems is the low transfection or transduction efficiencies, that make 
it difficult to interpret and compare results of the different shRNAs and siRNAs. A solution to overcome this 
problem is to include a reference gene146,147,150-152, but this makes the cloning experiments and the 
interpretation of results more complex. In our system, siRNA and shRNA delivery is not a major problem: 
transfection of siRNAs occurs through electroporation, which is highly efficient in the Ba/F3 suspension cell 
line. It was also not necessary to correct for differences in transduction efficiency, since we could perfectly 
measure the transduced cells only. All shRNA vectors also contained the GFP gene, so that we could gate 
on GFP positive cells for the shRNA experiments. So even with low transduction efficiency, we were able to 
observe differences between the different shRNAs. In addition, another advantage of using GFP labeled 
cells, instead of measuring luciferase activity, is the possibility of measuring several consecutive time points 
(over several days) with the same set of cells and the direct detection of fluorescence150. 
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A second advantage of the Ba/F3 cell system is that the cells can be made independent from the transcripts 
of interest (here the tPDGFRα fusion transcript) by the addition of IL-3. IL-3 is the ligand for the IL-3 receptor, 
which is expressed by the Ba/F3 cells and which can be used to drive the proliferation and the survival of the 
cells. In this way, addition of IL-3 will make the cells independent from the tPDGFRα fusion transcript, which 
can be used to investigate if the inhibitory effect observed by the RNAi molecules is due to a specific effect 
on the tPDGFRα fusion transcript or rather due to a non-specific effect. It is plausible that some shRNAs or 
siRNAs could target critical transcripts in the cell and in this way interfere with the proliferation of the Ba/F3 
cells. This would initially cause a false positive read-out in this system. However, when experiments are 
performed in the absence and also in the presence of IL-3, these false positive results can be detected 
easily. Finally, it could also be that the shRNA or siRNA target the PDGFRα part of the transcript, rather than 
the part of the gene of interest. Again, this can be easily detected by using the cells expressing the  
myc-tPDGFRα fusion, as these cells should not be inhibited by shRNAs or siRNAs specifically targeting the 
gene of interest. 
 
We can conclude that our validation system is an easy and reliable system to distinguish effective and  
non-effective shRNAs and siRNAs, and that this system can be used for the selection of the siRNAs and 
shRNAs with the appropriate knockdown characteristics. 
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2 Study of PTPRD as a candidate tumor suppressor in acute lymphoblastic leukemia and 
melanoma 
 
The obtained results of the role of PTPRD as a possible tumor suppressor in melanoma are in preparation 
for submission. 
 
INTRODUCTION 
 
The receptor tyrosine phosphatase gene PTPRD has been described as a tumor suppressor gene because 
it is frequently mutated, deleted or methylated (promotor methylation) in several types of cancer such as 
melanoma, GBM, neuroblastoma, lung and head and neck cancer66,68-70,103,106-108. Despite the fact that 
PTPRD is recurrently targeted in various tumors, functional confirmation that PTPRD is a bona fide tumor 
suppressor protein remains scarce. In the publications of Veeriah et al., Solomon et al. and Meehan et al. it 
has been shown that reconstitution of PTPRD expression in GBM, melanoma and neuroblastoma cell lines 
resulted in the suppression of the cell growth and the stimulation of apoptosis. In line, shRNA-mediated 
knockdown of PTPRD caused an increase in cell growth. Transduction of PTPRD deficient cell lines with 
PTPRD mutants resulted in a reduction of growth inhibition compared to wild type PTPRD69,70,111. Instead, 
Clark et al. could not confirm these results, since they observed no difference in the amount of colony 
formation in GBM and neuroblastoma cell lines after reconstitution of PTPRD158. Dephosphorylation of 
STAT3 by PTPRD has been associated with the effects of PTPRD on cell proliferation70. In neuroblastoma 
cell lines PTPRD dephosphorylates AURKA, which is a cell cycle regulated kinase involved in microtubule 
formation and stabilization of the MYCN oncogene111. These genomic and functional data suggest that 
PTPRD could act as a tumor suppressor gene in several tissues. However, the exact expression pattern of 
PTPRD is unknown, and the function of PTPRD together with the signaling pathways controlled by this 
negative regulator are poorly understood.  
 
Since PTPRD seems to be an important tumor suppressor in several solid cancers, we aimed to study in a 
first part the role of PTPRD as a tumor suppressor in the pathogenesis of ALL. Therefore, we analyzed gene 
expression, CNVs and mutation profiles of PTPRD in B-ALL and T-ALL cases. 
 
In a second part, we investigated the role of PTPRD in the development of melanoma since PTPRD was 
described to be frequently mutated (in 12% of the cases) in melanoma69. Because of the lack of functional 
and expression data, it is not clear whether the described mutations are real inactivating mutations or rather 
passenger mutations. Since the occurrence of passenger mutations in melanoma is high due to UV 
exposure, it is important to rule out possible passenger mutations. Therefore, we performed expression 
analysis in melanoma samples and in melanocytes, the cell of origin, to determine the expression levels and 
its correlation with CNV. 
 
The function of PTPRD and the signaling pathways controlled by this negative regulator are poorly 
understood. Therefore, we performed some functional experiments in 293T cells to identify downstream 
signaling proteins and to investigate the difference in enzymatic activity between PTPRD mutants and wild 
type. 
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RESULTS 
 
2.1 Loss of PTPRD does not contribute to the development of ALL 
 
The high frequency of PTPRD deletions in ALL correlates poorly with the gene expression levels 
 
Array-CGH data were analyzed with the Agilent Genomic Workbench and Array Studio software to define the 
percentage of CNV of the PTPRD gene. To determine the percentage of PTPRD loss in T-ALL patients we 
analyzed the array-CGH dataset of Gutierrez (42 samples)159, the array-CGH dataset of Maser  
(26 samples)160 and our array-CGH dataset (47 samples). In total, PTPRD was heterozygous deleted in 20 
out of these 115 T-ALL patient samples, which accounted for a high deletion frequency of 17,4%. It is 
remarkable that in all these cases the PTPRD deletions included the CDKN2A locus located 11 Mb 
downstream of PTPRD (Fig. 19A). The tumor suppressor, CDKN2A, is an important regulator of the cell 
cycle, which is frequently lost in many types of cancer, also in ALL. This raises the question in which extend 
loss of PTPRD is involved in T-ALL development next to the loss of CDKN2A. The PTPRD deletions can be 
passenger deletions because of the simultaneous loss with CDKN2A. Next, we performed expression 
analysis of our T-ALL sample to define the expression levels of PTPRD. The heatmap of our RNAseq data 
showed some variation in the PTPRD expression among the T-ALL samples (Fig. 19B). 
 
For the study of PTPRD loss in B-ALL patients, we analyzed the dataset of Russell (10 samples)161 and 
Kuiper (34 paired diagnosis and relapse samples)162. In these B-ALL patients PTPRD was heterozygous 
deleted in 10 out of 44 samples, which is a frequency of 22,7%. Of the nine patients with a PTPRD deletion 
observed in the dataset of Kuiper, four of the patients (ID 5, 11, 15 and 24) contained the PTPRD deletion in 
their diagnosis and relapse sample, three patients (ID 2, 9 and 10) had the PTPRD deletion in their diagnosis 
sample and two patients (ID 13 and 28) had PTPRD deleted in only their relapse sample. In six B-ALL 
samples with loss of PTPRD, the deletions included also the CDKN2A locus (Fig. 19C). To investigate 
whether the PTPRD deletions results in a reduction of the PTPRD expression level, we performed qRT-PCR 
and qPCR to define respectively the PTPRD expression levels and CNV in 13 B-ALL samples received from 
the group of dr. Kuiper (The Radboud University Nijmegen, The Netherlands). Two primer pairs located in 
exon 14 and 43 of PTPRD were used to determine the CVN. The T-ALL cell line, HSB-2, was used as a 
positive control for the primers used in the q(RT)-PCR. Although it is difficult to define the normal expression 
level of PTPRD in B-ALL samples with no loss of the PTPRD copy number, it seems that there is no 
correlation between the expression levels and the CNV. From the 5 B-ALL samples (IV-172, IV-149, IV-143, 
IV-55 and IV-99) with no expression of PTPRD only the IV-99 had a heterozygous deletion of PTPRD. For 
the 3 other samples the CNV was normal and for 1 sample the gDNA was not available to define the CNV. 
Further, there are four B-ALL samples (IV-140, IV-139, IV-99 and IV-92) with a heterozygous loss of PTPRD, 
which do also have a homozygous loss of CDKN2A (Fig. 19D). Although PTPRD and CDKN2A are both 
located on the p-arm of chromosome 9, it is not clear from our qPCR data whether the loss of 1 copy of 
PTPRD occurred together with loss of CDKN2A, since we do not have the information about the copy 
number of the 11 Mb between PTPRD and CDKN2A. Instead, the array-CGH data from dr. Kuiper showed a 
complete deletion of 9p in the IV-99 and IV-92 samples and mosaic deletions in 9p for the IV-140 and IV-139 
samples. Because of the high frequency of simultaneous loss of PTPRD and CDKN2A in B-ALL and the 
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array-CGH data of dr. Kuiper, we can assume that both genes are lost together because of the occurrence of 
bigger deletions in the p-arm of chromosome 9. Although the IV-140, IV-139 and IV-92 lost one copy of 
PTPRD, their mRNA level was not particular lower than the mRNA level in the samples with a normal CNV. 
One sample (IV-178) had an extremely higher mRNA level compared to the others although no increase of 
CNV was observed (Fig. 19D). Since our qPCR primers were located in exon 14 and 43, we could not detect 
smaller deletions in PTPRD outside these regions, which could affect the expression levels as well. Neither 
can we exclude that the expression levels are influenced by other mechanism than CNV. At least we would 
expect a reduction in expression level, when the CNV is lower, which is not the case in this B-ALL set. That 
is why we question the contribution of the loss of PTPRD in the development of ALL, although the 
percentage of PTPRD deletions is high. 
 
Figure 19. Expression level and copy 
number variation of PTPRD in T-ALL and B-
ALL samples (A) Regions of PTPRD deletions 
on chromosome 9, observed in three array-
CGH datasets of human T-ALL patient samples, 
are indicated with a horizontal line. In all cases 
the deleted regions included the PTPRD and 
CDKN2A locus. (B) Heatmap of RNAseq data 
visualizes the variation in PTPRD expression 
among T-ALL patient samples and cell lines. 
Red indicates a high expression and blue a low 
expression. (C) Regions of PTPRD deletions on 
chromosome 9, observed in two array-CGH 
datasets of human B-ALL patient samples, are 
indicated with a horizontal line. In 6 out of the 
10 B-ALL cases PTPRD was deleted together 
with CDKN2A in a bigger part. In the three other 
cases PTPRD and CDKN2A were lost in two 
different parts. One patient contained only a 
smaller deletion in the PTPRD locus. Deletions 
in diagnosis samples are indicated with a black 
line and relapse samples with a blue line. (D) 
Variation of PTPRD mRNA level in B-ALL 
patient samples did not correlate with the copy 
number of PTPRD. The four patient samples 
with heterozygous loss of PTPRD had a 
homozygous deletion of CDKN2A. A normal 
copy number is indicated with a yellow box, a 
heterozygous deletion with a blue box and a 
homozygous deletion with a black box. The T-
ALL cell line HSB-2 was used as a positive 
control for the primers used in the qPCR and 
qRT-PCR experiments. 
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Point mutations in PTPRD are rare in ALL 
 
When we assume that PTPRD is a tumor suppressor gene, we would expect to detect inactivating mutations 
in the patients with no deletions of PTPRD and in the patients with loss of only one copy. Therefore, we 
identified the amount of PTPRD mutations in two independent sets of ALL samples received from the group 
of prof. Soulier (University Paris-Diderot, France) (80 samples) and from the group of prof. Harrison 
(Newcastle University, UK) (75 samples) with the haloplex target enrichment technique and in our own T-ALL 
sample set with exome sequencing (48 samples). Exome sequencing is a technique of high-throughput 
sequencing of the coding regions of the genome, whereas Haloplex is a high-throughput technique, whereby 
selected genomics regions of interest are enriched and sequenced. We analyzed these datasets with the 
NextGENe software of Softgenetics. As parameters, we set the depth coverage at a minimum of 20 reads 
and the variant allele frequency needed to be higher than 20%. The variant allele frequency indicates how 
frequent the variant is present according to the total amount of reads. Variants present in a single nucleotide 
polymorphism database (dbSNP) are indicated in the software.  
 
The sequence analysis revealed only one single nucleotide variant 
(SNV) and four single nucleotide polymorphisms (SNPs) in five out 
of the 203 T-ALL patients. A SNP is a variation in the DNA 
sequence, whereby a single nucleotide differs between individuals. 
In contrast to a SNV, a SNP is assumed to not cause a disorder. 
These variants were validated with sanger sequencing. One of the 
four SNP (c.IVS20-8G>A) appeared in our exome sequencing 
dataset and was described in the 1000 genomes project (Table 5). 
This SNP was located in the extracellular part of PTPRD nearby the 
splice site region before exon 20 (Fig. 20). According to the Variant 
Effect Predictor (VEP) of Ensembl this SNP would not have a 
functional consequence. The three other SNP (D19V, R588C and 
R1559W), present in the dbSNP138, were found in the haloplex 
target enrichment dataset of prof. Soulier (Table 5). Two of these 
SNP (D19V and R588C) were located in the extracellular domain of 
PTPRD and the R1559W SNP was located in the first catalytic 
domain of PTPRD. The only SNV G920E appeared in the dataset of 
Soulier and was located in the extracellular domain of PTPRD  
(Fig. 20). With the SIFT and Polyphen prediction tools, we can 
predict whether these amino acid substitutions are affecting protein 
structure and function. According to the Polyphen tool the R588C 
and R1559W SNPs and the G920E SNV are probably damaging 
and the D19V SNP is benign. The SIFT tool indicates the D19V and 
R588C SNPs as tolerated, but the R1559W as deleterious  
(Table 5). These data indicate that PTPRD mutations are rare in  
T-ALL and it remains to be determined if the SNVs detected in this 
set of 203 T-ALL cases have functional consequences. 
Figure 20. Location of the PTPRD single 
nucleotide variations and single nucleotide 
polymorphisms observed in T-ALL cell 
lines and patient samples The location of the 
PTPRD single nucleotide variations (SNVs), 
indicated in black, and single nucleotide 
polymorphisms (SNPs), indicated in blue, 
observed in the T-ALL cell lines (left) and in 
the T-ALL patient samples (right). The SNPs 
are marked in blue and the SNVs in black. 
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Table 5. Single nucleotide variations and polymorphisms in T-ALL samples 
Variant SNV/SNP SNP 
database 
VEP SIFT Polyphen Sequencing 
database 
c.IVS20-7C>T SNP 1000 
genomes 
project 
No 
consequence 
/ / Cools 
D19V SNP dbSNP138 / Tolerated Benign Soulier 
R588C SNP dbSNP138 / Tolerated Probably 
damaging 
Soulier 
G920E SNV No / / Probably 
damaging 
Soulier 
R1559W SNP dbSNP138 / Deleterious Probably 
damaging 
Soulier 
 
 
PTPRD alterations and expression levels in T-ALL cell lines 
 
Western blot analysis and qRT-PCR showed some variation in PTPRD expression levels among our 18  
T-ALL cell lines (Fig. 19B and 21). The CNV of the PTPRD gene are determined with either array-CGH 
(indicated in black) or qPCR (indicated in blue) with primers located in exon 14 and 43. The variation in 
expression levels could only partially be explained by CNV. The reduced expression of PTPRD in the CCRF-
CEM and P12-ICHIKAWA cell lines can be the consequence of the heterozygous loss of the PTPRD gene 
(Fig. 21). The P12-ICHIKAWA harbors a mutation in the extracellular part of the protein in the remaining 
copy (Fig. 20). The MHH T-ALL cell line had a homozygous deletion of PTPRD and showed no expression. 
The PTPRD gene was duplicated in the HPB-ALL and the PEER cell line, but only the HPB-ALL had a high 
expression (Fig. 21). Besides P12-ICHIKAWA, four other cell lines contained a mutation in PTPRD. The  
P12-ICHIKAWA, JURKAT and the HSB-2 cell line had a mutation in the extracellular part and KARPAS-45 
and SUP-T1 had a mutation in the catalytic domain of the protein. With a mutation rate of 28%, the presence 
of mutation is much higher in cell lines compared to patient sample. This can be explained with the 
increasing occurrence of genomic alteration by keeping cell lines in culture.  
 
 
 
Figure 21. Expression level and genetic alterations of PTPRD in T-ALL cell lines The variation in PTPRD expression between the 
18 T-ALL cell lines was observed at the mRNA and protein level. This variation in expression level was only partially explained by a 
change in the copy number of PTPRD. The CNV was determined by array-CGH, indicated in black, or qPCR, indicated in blue. Four out 
of the 18 T-ALL cell lines had one or two point mutations in PTPRD. 
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Possible role of PTPRD in hematopoiesis  
 
Although the relevance of loss of PTPRD in ALL is not confirmed, it seems that PTPRD plays a role in the 
hematopoiesis. First indication is a higher expression of PTPRD in hematopoietic stem cells and early 
progenitors compared to more differentiated cells after analysis of the human hematopoietic cell expression 
data of Novershtern et al. (Fig. 22A). Novershtern et al. purified 38 distinct populations of human 
hematopoietic cells from umbilical cord and peripheral blood. After isolation of mRNA from each cell type, 
they performed expression profiles using Affymetrix microarrays163. The PTPRD gene expression profiles in 
the distinct hematopoietic cells were analyzed using the online available webtool of the Broad Institute 
(http://www.broadinstitute.org/dmap/home). Second, morphological examination of the spleen showed 
severe atrophy with reduction of the white and red pulpa in 16 weeks old Ptprd knockout mice housed in a 
specific pathogen free (SPF) facility. In 7-8 months old mice, housed in conventional facility, extramedullar 
hematopoiesis was observed in the spleen compared to control, because of a high amount of myeloid 
progenitors (Fig. 22B). These data indicate an important role of PTPRD in the hematopoiesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Higher PTPRD expression in undifferentiated hematopoietic cells and spleen defects in Ptprd knockout mice 
indicates a possible role in hematopoiesis (A) PTPRD expression levels drops along the differentiation process of the hematopoietic 
cells. (B) The 16 weeks old Ptprd knockout SPF mice had severe spleen atrophy with reduction of the white and red pulpa (left). 
Extramedullar hematopoiesis in the spleen of 7-8 months old conventional Ptprd knockout mice was observed because of a high 
amount of myeloid progenitors present in the spleen (right). 
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2.2 Loss of PTPRD does not contribute to the development of melanoma 
 
In literature is described that PTPRD is mutated in 12% of the melanoma cases69,70. Due to the lack of 
expression analysis and extensive functional experiments, it is not clear whether these mutations are real 
inactivating mutations or passenger mutations. Since the induction of passenger mutations in melanoma is 
high because of UV exposure, we aimed to study the role of PTPRD as a possible tumor suppressor in more 
detail. We started with performing mutation analysis to confirm the high mutation rate of PTPRD in 
melanoma. Next, we analyzed expression levels and CNV of PTPRD in melanoma. 
 
 
PTPRD is highly mutated in melanoma 
 
To determine the spectrum of PTPRD mutations in melanoma, we analyzed the exome sequencing datasets 
described by Hodis (121 samples)164, Krauthammer (91 samples)107 and The Cancer Genome Atlas (TCGA) 
initiative (262 samples). Our analysis revealed that 92 out of 474 patients had a missense (94,4%), 
nonsense (4,2%) or a splice mutation (1,4%) in PTPRD. This high mutation rate of 19,4% exceeded the 
previously described frequency of PTPRD mutations in melanoma. Compared to mutation frequency of 
PTPRD in other types of cancer, the frequency is the highest in melanoma (Fig. 23A). These mutations were 
found to be spread all over the gene (Fig. 23B). And more mutations were found in the introns (69,3%) 
compared to the exons (30,7%) of the exome sequencing dataset from Hodis et al. The high frequency of 
mutations in melanoma can be explained by UV exposure of the skin. The UVB radiation in sunlight induces 
mainly C to T or CC to TT transition by the formation of cyclobutane pyrimidine dimers (CPD). The CDP 
consists of a squared ring with four carbons arising from the coupling of the C=C double bonds of 
pyrimidines. These dimers interfere with base pairing during DNA replication, resulting in mutations. The 
cytosine in the CPD is prone to be deaminated, which induces the C to T transition165. In the analyzed 
datasets 40% of the PTPRD mutations contained a C to T transition and 3% a CC to TT transition. Of the 32 
PTPRD mutations present in the dataset of Krauthammer, 26 were found in sun-exposed melanoma with 
acral, mucosal or uveal origin. Furthermore, 29 of these 32 mutations contained the C to T or CC to TT 
transitions, which are typically induced by UV exposure. To determine if the detected mutations in PTPRD 
can be driver oncogenic mutations, we hypothesized that there would be an enrichment of mutations 
compared to mutations in introns due to selection. This was not the case for the mutations found in PTPRD, 
since 69,3% mutations were located in the introns compared to 30,7% in the exons. Instead, the BRAF and 
NRAS oncogenes and the TP53 tumor suppressor gene, in melanoma contained a higher percentage of 
mutations in the exons (respectively 90%, 93,8% and 85,2%) compared to the introns (respectively 10%, 
6,2% and 14,8%) (Table 6). Taken together, our mutation analyses were a first indication that the mutations 
in melanoma are passenger mutations. 
 
Table 6. Percentage of mutations located in exons and introns of oncogenes and tumor suppressor in melanoma 
Gene Mutation in exons (%) Mutation in introns (%) 
PTPRD 30,7 69,3 
BRAF 90 10 
TP53 85,2 14,8 
NRAS 93,8 6,2 
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Figure 23. Melanoma counts a high amount of PTPRD mutations with a distribution all over the gene (A) According to the 
cbioportal webtool the mutation rate of PTPRD is the highest in melanoma compared to other cancer types. (B) In three different 
sequencing datasets the mutations were spread all over the PTPRD gene and more missense than nonsense mutations were present. 
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PTPRD is expressed at very low levels in melanoma 
 
To further investigate the possible role of loss-of-function mutations of PTPRD in melanoma development, 
we performed and analyzed gene expression in melanoma cell lines and patient samples. In five melanoma 
cell lines there was no PTPRD mRNA or protein detected. Except from a heterozygous deletion of PTPRD in 
the COLO-800 cell line, this absence of PTPRD expression could not be explained by deletion of PTPRD 
(Fig. 24A). Analyses of gene expression profile datasets with Oncomine and Genevestigator showed that 
PTPRD is expressed at very low levels in melanoma samples. Point mutations are not necessarily affecting 
the PTPRD expression level, unless nonsense mutations introduce an earlier stop codon. As earlier 
described, the occurrence of nonsense mutations (4,2%) is not so high in melanoma compared to missense 
mutations (95,6%). Instead, CNVs have an influence on the protein expression levels, but homozygous 
deletions were observed in only 7 of the 262 (2,7%) patient samples of the TCGA dataset. Therefore, we 
analyzed mRNA levels and CNV in 12 mouse melanoma samples and in 57 human melanoma samples by 
performing qRT-PCR and qPCR. RNA quality was determined with the Bio-analyzer and samples with a RIN 
value below 5 were excluded from the experiment. The Ct values from the human and mouse melanoma 
samples clustered around the value of 30, which confirmed the very low expression of PTPRD in melanoma 
(Fig. 24B). Human melanoma samples with lower Ct values (between 25 and 28) could be assigned due to 
the lower Ct value of the B2M housekeeping gene or due to the lower percentage of tumor cells in the 
sample. Human and mouse melanoma tumor samples with a Ct value exceeding 30 for the melanocyte 
specific markers TYR and DCT were excluded from the analysis. Moreover, the expression level of PTPRD 
in healthy human melanocytes, the cell of origin of this cancer, was also extremely low (Ct values 30 or 
more) compared to other tissues like brain in which the functional role of PTPRD is more obvious (Fig. 24C).  
 
To define whether these low expression levels are the consequence of alteration in copy number, we 
compared the relative mRNA levels with the CNV in half of the human melanoma sample. In 15 samples with 
a heterozygous deletion of PTPRD only 8 samples had a low PTPRD mRNA level. For the samples with a 
high PTPRD mRNA level the copy number was not increased (Fig. 24D). Whether the increased mRNA 
levels of the samples in this graph indicate an effective increase in PTPRD expression is hard to conclude 
from this experiment, since the samples are compared against the low PTPRD expression in the melanocyte 
sample. We can conclude that the expression levels of PTPRD did not correlate with its CNV, as you would 
expect when tumor suppressor are lost in cancer. As in ALL, the loss of one copy of PTPRD could be 
assigned to the loss of the CDKN2A tumor suppressor, both located on the p-arm of chromosome 9. Except 
from 1 sample, all human melanoma samples with a deletion of PTPRD did also contain a deletion of 
CDKN2A. From our data it is not clear whether loss of PTPRD occurred together with loss of CDKN2A, due 
to the lack of the information about the CNV between the PTPRD and CDKN2A genes. We would expect that 
deletion of a tumor suppressor gene would result in an obvious reduction of its gene expression. Indeed, loss 
of the well-known tumor suppressor genes, PTEN and CDKN2A, in melanoma had indeed a much higher 
correlation between their expression and CNV, compared to PTPRD (Fig. 24E). Although there is not enough 
evidence from our study that PTPRD function as a tumor suppressor in melanoma, that doesn’t rule out the 
possible tumor suppressive role of PTPRD in other cancer types. For the cancer types with described 
PTPRD deletions, such as GBM, lung cancer and head and neck cancers, we generated correlation plots for 
PTPRD gene expression and CNV of the melanoma dataset of the TCGA-group using the cbioportal online 
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webtool. In GBM, lung cancer and head and neck cancer a small reduction in the expression level of PTPRD 
is observed when the gene is deleted (Fig. 25). A potential tumor suppressive role of PTPRD in these cancer 
types should be studied in more detail. 
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Figure 24 (opposite page). Expression level and copy number variation of PTPRD in melanoma cell lines and samples (A) The 
mRNA level (left) and protein level (middle) showed no PTPRD expression in the five human melanoma cell lines. Except from a 
heterozygous deletion of PTPRD in the COLO-800 cell line, this absence of PTPRD expression could not be explained by a change in 
copy number variation (right). (B) The PTPRD expression in human (left) and mouse (right) melanoma samples is very low, because the 
Ct values cluster around 30. Tumor samples with a Ct value of 30 or higher for the melanocyte specific markers TYR and DCT were 
excluded from the analysis. The human and mouse B2M genes were used as a housekeeping gene to rule out high differences in 
mRNA starting material. (C) The PTPRD expression in the melanocytes from healthy donors is extremely low compared to other human 
tissues. (D) Variation of PTPRD mRNA level in melanoma patient samples did not correlate with the copy number of PTPRD. Except 
from one sample, all the patient samples with a heterozygous loss of PTPRD had lost at least one copy of CDKN2A. A normal copy 
number is indicated with a yellow box, a heterozygous deletion with a blue box and a homozygous deletion with a black box. The human 
melanocyte was used as a reference sample in the qPCR and qRT-PCR analysis. (E) Comparison of PTPRD expression level and CNV 
showed no correlation in the public available dataset of the TCGA-group using the cbioportal web tool. Instead, there is an obvious 
reduction in the gene expression of the known tumor suppressor genes PTEN and CDKN2A, when these genes are lost in melanoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Correlation plots of PTPRD expression levels and copy number variation in glioblastoma multiforme, lung cancer 
and head and neck cancer The correlation between the PTPRD expression levels and CNV was analyzed in two different dataset of 
the glioblastoma multiforme (GBM), lung and head and neck cancer types. Deletions of PTPRD were previously reported for these types 
of cancer. There is small reduction in the mRNA level of PTPRD when the gene is deleted in (A) GBM, (B) lung cancer and (C) head 
and neck cancer. 
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The STAT1 and STAT3 proteins as substrates of PTPRD in 293T cells 
 
Although it seems that PTPRD is not involved in the development of melanoma and ALL, we confirmed 
STAT3 as a substrate of PTPRD and identified STAT1 as a yet unknown substrate in 293T cells. We used 
the 293T cells as model to analyze the phosphatase activity of wild type PTPRD and mutants. The 293T 
cells were transfected with a ½ dilution serie from 1 to 0 µg DNA of the PTPRD wild type and mutant 
constructs. The level of substrate dephosphorylation was indicative for their phosphatase activity. 
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Figure 26 (opposite page). Study of the phosphatase activity of wild type PTPRD and mutants in 293T cells (A) The PTPRD long 
and short isoform are fully catalytic active, since a higher expression level resulted in a bigger decrease in pSTAT1 and pSTAT3 
compared to lower expression levels. Instead, there was no difference in the phosphorylation level of STAT1 and STAT3 among the 
several expression levels of the catalytically inactive PTPRD D1115A mutant. (B) The PTPRD mutants P459L, P1690F and G1707R 
seems to act as oncogenes, since higher expression levels of these mutants resulted in a higher pSTAT1 and pSTAT3 level. No 
difference in the phosphorylation level of STAT1 and STAT3 was observed for the PTPRD mutants G446E and D1248N. (C) Location in 
the PTPRD gene of the five PTPRD mutants identified in melanoma and GBM. (D) The oncogenic effect of the PTPRD G1707R mutant, 
which was seen in panel B, could not be repeated. 
 
 
Increasing expression levels of the wild type long and short isoform of PTPRD resulted in a higher 
dephosphorylation of STAT3 and also STAT1. In contrast the enzymatically inactive protein PTPRD D1115A 
was no longer able to dephosphorylate its substrates (Fig. 26A). The STAT proteins are well known 
transcription factors that promote cell proliferation. The PTPRD proteins seem to have a tumor suppressive 
role, because they are able to dephosphorylate the STAT1 and STAT3 proteins. The effect of the PTPRD 
point mutations on its phosphatase activity was analyzed by studying the phosphorylation status of STAT1 
and STAT3 in 293T cells after transfection with the PTPRD mutants. The five PTPRD mutants were located 
in the extracellular and intracellular part of PTPRD (Fig. 26B) and were previously identified in melanoma or 
GBM cases69. Remarkably, higher expression levels of the PTPRD P459L, P1690F and G1707R mutants 
induced a higher phosphorylation of STAT1 and STAT3, suggesting an oncogenic role (Fig. 26C). 
Unfortunately, we were not able to reproduce this result in 293T cells (Fig. 26D). Other models should be 
used to study the effect of the mutation on the PTPRD phosphatase activity, since the results from the 293T 
model is inconclusive. 
 
 
DISCUSSION 
 
Previous publications report PTPRD as a candidate tumor suppressor gene, because the gene is frequently 
lost in several solid tumors. A possible role of PTPRD as a tumor suppressor in hematological malignancies 
was not yet described. We observed a high frequency of heterozygous deletions of PTPRD in array-CGH 
datasets of T-ALL and B-ALL cases. Remarkably, almost in all cases the PTPRD gene was lost in a bigger 
part together with the CDKN2A gene. This simultaneous loss questions the relevance of PTPRD as a tumor 
suppressor next to the well-known tumor suppressor CDKN2A. The CDKN2A is a cell cycle regulator, whose 
losses contribute in many cancer types to development of the malignant cells. Deletion of a tumor 
suppressor gene would result in a reduction of its expression level. Unfortunately, our expression analysis of 
PTPRD in the B-ALL samples does not correlate with the CNV analysis of the gene. According to the two-hit 
hypothesis, loss of only one copy of PTPRD can be insufficient to inactivate a tumor suppressor gene166. 
Because PTPRD is frequently heterozygous deleted in ALL, we performed a mutations analysis in T-ALL 
samples. We observed only one SNV and four SNP in the T-ALL samples. In T-ALL cell lines the frequency 
of PTPRD mutations was higher than in the patient samples, but this can be due to long time culture of the 
cell lines. Mutations are unlikely to be involved in the inactivation of PTPRD in T-ALL, because of their low 
frequency. Of course we can’t exclude other mechanisms, such as promoter methylation or regulation by 
miRNAs, which causes the observed variation in PTPRD expression levels in ALL. From our results we have 
reason to doubt about the tumor suppressive role of PTPRD in ALL, because the reduction in expression 
level does not correlate with a lower CNV and the high frequency of PTPRD deletions can be a consequence 
of the simultaneous loss of CDKN2A due to large deleted regions on Chr9p. Although we couldn’t prove the 
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tumor suppressive role in ALL, we showed first evidence that PTPRD might be involved in the 
hematopoiesis. The Ptprd knockout mice had a severe spleen atrophy and extramedullary hematopoiesis in 
the spleen. Hematopoiesis that occurs in organs other than the bone marrow is called extramedullary 
hematopoiesis. Since the extramedullary hematopoiesis was observed in conventional Ptprd knockout mice, 
which are not pathogen free, the extramedullary hematopoiesis can be caused because of an active immune 
response to pathogens. Therefore, analysis of Ptprd knockout mice housed in a SPF facility can obtain more 
insights. The extramedullary hematopoiesis in the spleen can also occurs when the bone marrow is failing in 
sustaining the hematopoiesis. For examples, due to myelofibrosis, hematopoietic cells will migrate outside 
the bone marrow167. However, H&E staining of the bone marrow showed no morphological differences with 
control mice. Another indication for the role of PTPRD in hematopoiesis is the higher PTPRD expression 
level in hematopoietic stem cells and progenitor cells compared to differentiated cells. The potential role of 
PTPRD in the hematopoiesis should be investigated in more detail by performing flow cytometry analysis 
and more morphological analysis of the hematopoietic tissues of Ptprd knockout mice in order to confirm the 
preliminary data and to understand the underlying mechanism of this phenotype.  
 
Besides our study of the tumor suppressive role of PTPRD in ALL, we also investigated its role in melanoma 
because a high frequency of PTPRD mutations was described in this malignancy. In general the mutation 
rate in melanoma is high due to sun exposure and therefore also the occurrence of passenger mutations is 
high. From the literature it is not clear whether the described PTPRD mutations are inactivating or passenger 
mutations because the biological relevance of these mutations was not studied in great detail. Our 
expression analyses showed a very low expression of PTPRD in human melanoma cell lines and in human 
and mouse melanoma samples. Even in the melanocytes, which are the cells of origin of the melanoma, the 
PTPRD expression is extremely low. Because of low PTPRD expression level in melanoma and 
melanocytes, its biological function in this malignancy is under question. When UV irradiation induces 
passenger mutations in the PTPRD gene, we would expect at least as many mutations in the introns as in 
the exons. Mutations in the untranslated regions of the gene will not give a proliferative advantage to the 
cells, unless it interferes for example with its splicing. Indeed, we observed the double amount of mutations 
in the introns than in the exons. Compared to known oncogenes, BRAF and NRAS, and tumor suppressor 
gene, TP53, the amount of mutations in the exons is higher because they provide a proliferative advantage 
to the cells, which results in their selection. Mostly these mutations are present in more than one patient 
sample and are therefore called hotspots. For example the BRAF V600E mutant is present in 80% of the 
melanoma cases. We did not observe any mutation hotspot in the PTPRD gene. Instead, the mutations were 
spread all over the gene, which indicates the more randomized introduction of the passenger mutations in 
the PTPRD gene. However, that doesn’t mean that substitutions at several places in the gene could not 
affect its protein activity or function. The typically UV-induced C to T transitions were also high in the PTPRD 
gene. These observations from our mutational analysis indicate that the PTPRD mutations are likely to be 
passenger mutations. However this high rate of PTPRD mutations does not explain the low expression levels 
in melanoma and even low protein levels can have an important cellular function. If PTPRD is an important 
tumor suppressor in melanoma, we would expect even lower expression levels when the gene was deleted. 
In fact our comparison between gene expression and CNV in human and mouse melanoma samples 
showed no correlation. All together our data indicate that mutations and deletions found in melanoma are 
unlikely to be relevant for the development of the tumor. 
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Our functional studies in 293T cells confirmed STAT3 as a downstream signaling protein of the long and 
short isoform of PTPRD and identified STAT1 as a new downstream target of PTPRD. In contrast to the wild 
type PTPRD, some PTPRD mutants had an oncogenic effect by increasing the STAT1 and STAT3 
phosphorylation. Although we could not repeat this effect in 293T cells, Lui et al. published the same 
observation with PTPRT mutants in head and neck squamous cell carcinomas. Overexpression of PTPRT 
proteins with mutations in their catalytic domain in head and neck squamous cell carcinoma resulted in an 
increased STAT3 phosphorylation. Their computational modeling of the PTPRT mutations showed that these 
mutations interfere with phosphatase activity and/or substrate interactions. Furthermore almost 50% of the 
PTPRT mutations were located in the phosphatase domain, supporting the relevance of their interference 
with the enzymatic activity. In general this group found a significant association between mutations in the 
receptor PTPs, including PTPRD, and increased pSTAT3 levels168. A possible oncogenic effect of the 
PTPRD mutants by increasing pSTAT3 levels should be further investigated in a relevant tumor model.  
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2.3 The identification of PTK2B as a downstream target of PTPN2 
 
INTRODUCTION 
 
The Protein Tyrosine Phosphatase, non-receptor type 2 or PTPN2 is an intracellular, non-transmembrane 
phosphatase, which is highly expressed in hematopoietic cells. The PTPN2 protein is highly expressed in 
hematopoietic cells and its absence accounts for the defects in hematopoiesis observed in the PTPN2 
knockout mice, which die within 3 to 5 weeks due to immunological dysfunction117,121. Studies in T-cell 
specific deficient mice indicate PTPN2 as a negative regulator of TCR signaling that sets the threshold for 
TCR-induced naïve T-cell response122. The identification of SNP upstream of the PTPN2 locus implicates it 
role in human autoimmune diseases169. Furthermore, PTPN2 has also been implicated in cancer 
development and is considered as a tumor suppressor in T-ALL, Hodgkin lymphoma and T-cell non-hodgkin 
lymphoma43,44,129. However, the downstream pathways, regulated by PTPN2 in leukemia development and 
progression, are not yet completely understood. 
 
In T-ALL, focal deletions of PTPN2 are observed in about 6% cases, and it was shown that loss of PTPN2 
leads to an increased signaling downstream of the IL-2 and IL-7 cytokine receptors in leukemic cell lines. 
These observations suggest that loss of PTPN2 enhances the response of T-ALL cells to these cytokines 
and provides the leukemia cells with a growth advantage43. In addition, it was observed that loss of PTPN2 
frequently co-occurs with the NUP214-ABL1 fusion or with mutation of JAK1. Indeed, overexpression of 
these oncogenic kinases (NUP214-ABL1 or mutant forms of the JAK1 kinase) together with knockdown of 
PTPN2 accelerated the transformation of leukemic cells in vitro, demonstrating cooperation between these 
oncogenic lesions43,44.  
 
It is now established that PTPN2 is a negative regulator of JAK/STAT signaling, and a negative regulator of 
the NUP214-ABL1 fusion protein. However, it is hypothesized that PTPN2 can regulate additional signaling 
pathways in T-ALL. Therefore, to identify additional signaling pathways regulated downstream of PTPN2 we 
performed phospho-proteomic analysis in the “Mouse Hematopoietic Interleukin-dependent cell line of T-cell 
Origin” (MOHITO) cell line. The MOHITO cells are a murine CD4+CD8+ double positive T-cell line, extracted 
from a sublethally irradiated Balb/c mouse, which developed a leukemic disease. The cell line contains both 
the NOTCH1 and JAK1 mutations, which are typical genetic alterations of the T-ALL disease. The MOHITO 
cells are dependent on the IL-2 and IL-7 cytokines for cell proliferation by activating the JAK/STAT pathway 
and as such the MOHITO cell line is considered an ideal cell model to study signaling pathways controlled by 
PTPN2 in the development of T-ALL156. 
 
 
RESULTS 
 
Phospho-proteomics revealed 38 proteins downstream of PTPN2 
 
To identify the signaling pathways governed by PTPN2 we performed phospho-proteomic analysis in 
MOHITO cells. Therefore, MOHITO cells with knockdown of Ptpn2 and untransduced MOHITO cells were 
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cultured in growth medium with either heavy or unlabeled arginine and lysine. After cell expansion, cell 
lysates were made from both cultures and mixed in a 1:1 ratio. By performing immunoprecipitation with two 
phospho-tyrosine specific antibodies we purified the substrates with tyrosine residue phosphorylation. The 
purified proteins were separated using gel electrophoresis. After visualization of the proteins with coomassie 
staining, the gel was cut in small pieces for in-gel digestion with trypsin. Trypsin cleaves peptides at the  
C-side of arginine and lysine, except when either one is followed by proline, resulting in small peptide 
fragments. Identification of these fragments occurred in a last step by mass spectrometry. In total, 38 
proteins were identified that had 1,5 fold higher phosphorylation in the MOHITO cells with knockdown of 
Ptpn2 compared to the control cells. We classified these downstream signaling proteins of PTPN2 into five 
groups according to their known role in T-cell signaling, immunological synapse, proliferation-survival and 
migration-adhesion as described in publications (Fig. 27A). 
 
 
 
 
 
 
 
 
 
 
 
 
  B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Phospho-proteomics identified 38 proteins downstream of Ptpn2 in MOHITO cells (A) Phospho-proteomics identified 
38 proteins downstream of Ptpn2 in MOHITO cells, which are grouped according to their known role in T-cell signaling, formation of 
immunological synapse, proliferation and survival or migration and adhesion. (B) The STRING analysis visualizes a cluster of predicted 
protein interactions between proteins involved in T-cell signaling and immunological synapse formation based on information derived 
from previously reported genomic analysis, high-throughput experiments, co-expressions and publications. (C) Protein-analysis 
confirmed a higher phosphorylation of Cbl, Ptk2b and the Src family member, Lck in MOHITO cells with shRNA-mediated knockdown of 
Ptpn2 compared to control cells. 
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To find out which of the 38 proteins from our phospho-proteomics experiment are already known to interact 
with each other, we performed a STRING-analysis. STRING stands for Search Tool for the Retrieval of 
Interacting Genes/proteins and is a database of known and predicted protein interactions. The interactions 
include direct, physical and indirect, functional associations, which are derived from four sources: genomic 
context, high-throughput experiments, co-expression and previous knowledge (PubMed). The STRING 
analysis showed a cluster between the proteins involved in T-cell signaling and immunological synapse 
formation (Fig. 27B). In that way the STRING-analysis confirmed our phospho-proteomics results by 
indicating that PTPN2 is involved in several signaling pathways important in T-cell immune response. 
Defects in these pathways can explain the development of autoimmune diseases in patients with a SNP 
located upstream of the PTPN2 locus. Since we are interested in the mechanisms underlying the cause of  
T-ALL, we decided to focus more on signaling proteins involved in cell growth rather than in immune 
response. 
 
To confirm the phospho-proteomics results, we analyzed the level of tyrosine phosphorylation of proteins 
from cell lysates of MOHITO cells with Ptpn2 shRNA-mediated knockdown versus control cells. We 
confirmed a higher tyrosine phosphorylation of Cbl, Ptk2b Tyr402 and Lck Tyr394 in the MOHITO cells with a 
downregulation of Ptpn2 compared to the control cells (Fig. 27C).  
 
Further in this study we focused on the role of PTK2B, also named PYK2, in the development of T-ALL. The 
non-receptor tyrosine kinases, the focal adhesion kinase (FAK) and the proline-rich tyrosine kinase 2 
(PTK2B) form together the FAK family and link the TCR and growth factor receptor signaling to proliferation, 
survival, apoptosis and migration170-173. After TCR stimulation PTK2B is phosphorylated and activated by 
FYN, where after PTK2B will modulate the actin cytoskeleton through phosphorylation of paxillin170,172,174. 
Overexpression of PTK2B promoted migration in glioma cells. Beside its role in migration, PTK2B promotes 
also cell proliferation downstream of the IL-2 and IL-7 receptor173. Stimulation of these receptors by their 
cytokines in T-cells results in a rapid phosphorylation and activation of PTK2B. Downregulation of PTK2B in 
these cells results in a reduction of cell proliferation175,176. The IL7-R/JAK-STAT pathway is an important 
signaling pathway in T-cell for their proliferation and is often constitutively activated through mutations in the 
IL7-R, JAK1 or JAK3 proteins in T-ALL43-45. RNA-seq analysis by Atak et. al found PTK2B as a new 
candidate driver gene in T-ALL177. Taking these findings together, PTK2B seemed for us an interesting 
signaling molecule to study its contribution in the development of T-ALL. 
 
 
Rapid activation of Ptk2b is induced after short-term IL-2 and IL-7 stimulation and loss of PTPN2 
extended its return to baseline 
 
It was previously described that IL-2 and IL-7 stimulation of thymocytes results in a rapid phosphorylation of 
PTK2B175,176. After a cytokine starvation period of 3 hours, stimulation of our murine T-cell line MOHITO with 
IL-2 and IL-7 during several time points resulted as well in rapid activation of Ptk2b. The maximum 
phosphorylation of Ptk2b was obtained after 10-15 minutes of cytokine stimulation after which the 
phosphorylation decreased again to baseline, although activation of Jak1 was retained (Fig. 28A and C). We 
observed also a rapid phosphorylation of downstream signaling proteins of Ptk2b such as Mek1/2 and Erk1/2 
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(Fig. 28A). This rapid increase in Ptk2b, Mek1/2 and Erk1/2 phosphorylation after cytokine stimulation was 
also seen in two mouse leukemia cell lines derived from a JAK3 L857Q bone marrow transplant mice  
(Fig. 28B). Knockdown of Ptpn2 in MOHITO cells resulted in a slower return to baseline of the Ptk2b 
phosphorylation after IL-7 stimulation compared to the control cells (Fig. 28C). These data indicate that 
Ptpn2 is a negative regulator of Ptk2b signaling downstream of the IL-7 receptor pathway in T-cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Rapid activation of Ptk2b after IL-2 and IL-7 stimulation in mouse T-cell leukemic cell lines is negatively regulated 
by PTPN2 (A) Short-term stimulation of MOHITO cells with IL-2 and IL-7 cytokines results in a rapid phosphorylation of Ptk2b and the 
more downstream signaling proteins, Mek1/2 and Erk1/2, whereas phosphorylation of Jak1 holds on. (B) Also short-term stimulation of 
two mouse Jak3 leukemia cell lines results in a rapid phosphorylation of Ptk2b and the more downstream signaling proteins, Mek1/2 
and Erk1/2. (C) In MOHITO cells, phosphorylation of Ptk2b reaches its maximum by 15 minutes of IL-7 stimulation, where after it returns 
again to baseline (left). A slower return to baseline was observed in MOHITO cells with knockdown of Ptpn2 (right). 
 
 
Src activates Ptk2b downstream of the IL-7 receptor 
 
The PTK2B protein consists of a FERM, kinase and FAT domain. The FERM and FAT domains are involved 
in the interaction with signaling proteins. The kinase domain is important for the enzymatic activity of the 
protein after phosphorylation of the tyrosine residue 580 (Fig. 29A). The mechanisms of PTK2B activation 
differ depending on the activation of the upstream receptors. Activation of cytokine receptors in neuronal, 
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epithelial and hematopoietic cells results first in Ca2+ influx, activation of PI3K or actin remodeling which lead 
to phosphorylation of the first tyrosine residue of PTK2B, Tyr402. Thereafter, SRC kinases will activate the 
second tyrosine residue, Tyr580, resulting in enzymatically activation of the PTK2B protein. Instead, 
activation of the TCR after binding with the major histocompatibility complexes (MHC) of the antigen 
presenting cell (APC) results first in activation of the SRC kinases LCK or FYN. These SRC kinases will 
activate the PTK2B protein by phosphorylating the TYR402 and the TYR580 residues (Fig. 29B)174. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. PTK2B structure and regulation (A) Schematic representation of the PTK2B protein, which consist of a FERM, kinase and 
FAT domain. The four tyrosine residues (Y) are indicated. (B) Regulation of PTK2B, also named PYK2, activation is different 
downstream of cytokine receptor or TCR receptor. Stimulation of a cytokine receptor causes first a Ca2+ influx, activation of PI3K or actin 
remodeling, which will result in the phosphorylation of Tyr402. Next, the SRC kinase phosphorylates Tyr580 for the enzymatic activation 
of PTK2B (left). Activation of the TCR activates first the SRC kinases, which will simultaneously phosphorylate the Tyr402 and the 
Tyr580 of the PTK2B protein. (Adapted from reference174) 
 
 
We studied how Ptk2b got activated downstream of the IL-7 receptor by performing SRC inhibitor 
experiments. After treatment with the SRC inhibitors, AZD0530 and dasatinib, Ptk2b phosphorylation was 
completely blocked even after stimulation with IL-7 in MOHITO cells and in two mouse Jak3 mutant leukemia 
cell line (Fig. 30A and B). This result showed that Ptk2b phosphorylation downstream of the IL-7 receptor is 
completely dependent on the Src kinases. 
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Figure 30. Inhibition of Src kinases blocked activation of Ptk2b (A) Treatment of MOHITO cells with the SRC inhibitors AZD0530 
and dasatinib, inhibited Ptk2b phosphorylation after IL-7 stimulation. (B) Also treatment of two leukemic T cells, derived from the Jak3 
L857Q bone marrow transplant mice, with the AZD0530 and dasatinib SRC inhibitors blocked phosphorylation of Ptk2b after stimulation 
with IL-7. 
 
 
PTK2B is not involved in T-cell proliferation or migration 
 
Since PTK2B is involved in the IL-7R JAK/STAT pathway we assumed that PTK2B would also play a role in 
T-cell proliferation. However, siRNA-mediated Ptk2b knockdown in MOHITO cells had no effect on their cell 
growth. A siRNA targeting Jak1 was used as a positive control, since knockdown of Jak1 results in a 
reduction of cell proliferation in MOHITO cells (Fig. 31A). Since the IL-7R LSRC, the JAK1 A634D, the JAK3 
M511I and JAK3 L857Q mutants transform the MOHITO cells, we wondered whether Ptk2b contributes in 
this proliferative advantage. However, siRNA-mediated knockdown of Ptk2b did not affect the cell growth of 
the transformed MOHITO cells. Only knockdown of Jak1 in the transduced MOHITO cells with the  
IL-7R LSRC and JAK3 M511I mutants caused a decrease in cell proliferation because they are still 
dependent on Jak1 for their growth (Fig. 31A). Neither inactivation of Ptk2b by treating the MOHITO cells 
with SRC inhibitors, AZD0530 and dasatinib, had an effect on their growth (Fig. 31B). We supposed that 
combination treatment of MOHITO cells with SRC and JAK inhibitors would have an effect on cell 
proliferation, since Ptk2b is downstream of the IL-7R pathways and gets activated by Src. Instead,  
dose-response curves of the JAK inhibitors ruxolitinib and tofacitinib showed no differences in combination 
with AZD0530 treatment compared to the DMSO control (Fig 31C). 
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Figure 31. Inactivation of Ptk2b does not affect the proliferation of the T-cell leukemic cell line (A) SiRNA-mediated knockdown of 
Ptk2b had no effect on the cell proliferation of the untransduced MOHITO cells or the transformed MOHITO cells by the IL-7R LSRC, 
JAK1 A634D, JAK3 M511I and JAK3 L857Q mutants compared to the scrambled controls. The siRNA targeting Jak1 was used as a 
positive control, which reduced the proliferation of the untransduced MOHITO cells and IL-7R LSRC and JAK3 M511I transduced 
MOHITO cells. Mean growth ± SEM was recorded in triplicate for 3 days. (B) Inactivation of Ptk2b by the SRC inhibitors AZD0530 (left) 
and dasatinib (right) had no effect on the cell proliferation of the untransduced and transformed MOHITO cells. Mean growth ± SEM was 
recorded in fivefold on day 0 and 1. Relative proliferation percentage was calculated by setting cell growth of untreated cells to 100%. 
(C) Dose-response curves showed no difference in growth percentage of MOHITO cells when treated with AZD0530 in combination with 
the JAK inhibitors ruxolitinib or tofacitinib compared to the DMSO and AZD0530 as a control. The error bars indicate SEM. 
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Besides its role in proliferation, PTK2B is known to be involved in cell migration by regulating the actin 
cytoskeleton. Since we showed that inactivation of Ptk2b had no effect on cell proliferation in MOHITO cells, 
we investigated its role in cell migration by performing a migration assay. Therefore, we used ThinCerts with 
a pore size of 8 µm, which were placed in a 24-well plate filled with 20% growth medium. The MOHITO cells, 
resuspended in 5% growth medium, were added to the ThinCerts. A final concentration of 100 nM AZD0530 
and dasatinib were added to the medium of the insert and the well to inhibit Ptk2b activation. After an 
incubation time of 6 hours the amount of viable cells in the well and the ThinCert was measured to calculate 
the percentage cell invasion. Their was no difference in the percentage cell invasion between cell treated 
with the SRC inhibitors compared to the control cells treated with DMSO (Fig. 32). These data indicate that 
Ptk2b is not involved in the migration of the MOHITO cells. 
 
 
Figure 32. Inactivation of Ptk2b had no effect on the 
cell migration of the T-cell leukemic cell line The 
migration assay showed no significant difference (p>0,05) 
in percentage cell invasion between MOHITO cells treated 
with the SRC inhibitors AZD0530 and dasatinib compared 
to the DMSO control. The migration assay was performed 
in triplicate. The significance was determined by the  
Mann-Whitney test. 
 
 
 
 
 
 
 
DISCUSSION AND CONCLUSION 
 
Previous studies described that the non-receptor protein tyrosine phosphatase, PTPN2, is a negative 
regulator of the JAK/STAT pathway. Loss of PTPN2 by deletions occurred in 6% of the T-ALL cases and was 
associated with the presence of JAK1 mutations and NUP214-ABL1 fusion genes. Loss of the negative 
regulator PTPN2 increases the oncogenic activity of the JAK1 mutants and the NUP214-ABL1 fusion protein, 
which enhances the transforming capacity of the leukemic cells. Since the JAK1 mutants and NUP214-ABL1 
fusion proteins were present in only a small group of the PTPN2-negative T-ALL cases, other oncogenic 
kinases are assumed to be involved in the pathogenesis of T-ALL downstream of the PTPN2 phosphatase. 
In this part of the project we aimed to identify the other signaling pathways controlled by PTPN2 by 
performing phospho-proteomics in the IL-7 dependent murine leukemic T-cell line, MOHITO, with and 
without knockdown of PTPN2. Analysis of the phospho-proteomics data identified 38 proteins with a 1,5 fold 
increase in their phosphorylation when PTPN2 was downregulated in the MOHITO cells. According to their 
biological function described in research publication we grouped the identified proteins into five classes:  
T-cell signaling, immunological synapse, proliferation-survival, migration-adhesion and others. 
 
Since PTPN2 plays an important role in immune response it is not so remarkable that a large group of the 
identified phospho-proteomics proteins are involved in T-cell signaling and immunological synapse 
formation. A first step in the T-cell immune response is the binding of the TCR of the T-cell to the  
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peptide-major histocompatibility complex (MHC) of the antigen-presenting cell (APC). The TCR consists of a 
heterodimer with TCRα and TCRβ chains or TCRγ and TCRδ chains, which can bind the peptide-MHC 
complex, but lacks intracellular signaling transduction motifs. Therefore, the CD3 γ, δ, ε and ζ chains, 
containing the immunoreceptor tyrosine-based activation motifs (ITAMs), are bound in three dimers (γε, δε 
and ζζ) to the TCR178. The CD3ζ, also called CD247, was one of the phospho-proteomic outcomes. The 
TCR/peptide-MHC complex is stabilized after binding of the CD4 or CD8 co-receptor with the MHC molecule. 
The SRC kinases, LCK and FYN, are thereafter recruited which phosphorylate the tyrosine residues in the 
ITAMs. Subsequent the ZAP-70 kinase is recruited to the TCR complex, where it is phosphorylated and 
activated by LCK. The ZAP-70 kinase per se will phosphorylate the LAT and SLP-76 adapter proteins, which 
results on the one hand in cytoskeletal rearrangement and on the other hand in cytokine production, 
proliferation and survival by regulating gene transcription through activation of the RAS pathway and 
mobilization of Ca2+. In this way TCR signaling enhances and maintains the T-cell immune response179-182. 
 
Not so surprising is the presence of the SRC family kinases, FYN and LCK, in our phospho-proteomics data, 
since PTPN2 is a known negative regulator of the TCR signaling by dephosphorylating LCK. The increased 
LCK activation, due to the Ptpn2 deficiency in the naïve T cells from the Lck-Cre;Ptpn2fl/fl mice, enhanced the 
TCR activation and proliferation and lowered the TCR threshold response to low-affinity antigens. These 
increased T-cell responses to low-affinity ligands may explain the inflammatory and autoimmune phenotype 
in the Lck-Cre;Ptpn2fl/fl mice122. The SRC family kinase are not only important during TCR signaling, but also 
at several stages of T-cell development, such as pre-TCR signaling, positive selection and homeostasis of 
naïve T-cells180.  
 
The IL-2 cytokine production after T-cell activation is an important T-cell immune reaction. IL-2 is secreted by 
the T-cell and binds to the IL-2 receptors present in the membrane of the same T-cell to promote clonal 
expansion and acquisition of effector or memory function. The IL-2 receptor consists of the α, β and γ chain. 
The JAK1 kinase is bound to the IL-2 receptor β chain and the JAK3 kinase to the IL-2 receptor γ chain. The 
IL-2 receptor β chain (or IL2Rb) appeared in our phospho-proteomics results182. 
 
A negative regulator of the T-cell receptor signaling is the C-terminal SRC kinase (CSK). CSK 
phosphorylates the C-terminal tyrosine residue of LCK and FYN, which results in an inactive confirmation of 
the enzyme. CSK is located in the proximity of the SRC kinases through its association with the lipid raft 
targeted transmembrane adapter protein, PAG. The CSK-PAG binding is possible because of the 
phosphorylation of PAG by FYN, showing that the SRC family kinases regulate their own activity. After TCR 
stimulation PAG is dephosphorylated, resulting in the release of CSK and which favor LCK and FYN 
activation. CSK and PAG were present in our phospho-proteomics data179-181. 
 
Binding of the TCR with the peptide-MHC complex results in the formation of an immunological synapse 
between the T-cell and the APC. After stimulation of the TCR, the TCR signaling cascade induces 
remodeling of the cytoskeleton to cluster integrins around the TCR complex. In that way the immunological 
synapse is stabilized to sustain T-cell activation and proliferation. The process of remodeling the 
cytoskeleton involves a cluster of signaling pathways of which some signaling molecules appeared in our 
phospho-proteomics dataset, such as FYN, FYB, PTK2B, PSTPIP1, HCLS1, SKAP1 and ILK170,179,183-187. 
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Two negative regulators, DBNL and CBL, of the immunological synapse and the TCR signaling cascade 
were also present in our dataset. DBNL is part of the immunological synapse and reduces TCR expression 
by gene regulation via the NFAT transcription factor188. CBL inhibits the formation of the immunological 
synapse by repressing TCR activation in the absence of the CD28 co-stimulator189.  
 
The third group of our phospho-proteomics data contains the proteins involved in proliferation and survival 
either in positive or negative way. The receptor tyrosine kinase, KIT, has an important role in the 
maintenance and survival of hematopoietic stem cells and is negatively regulated by CBL190. It is a known 
oncogene in cancer, such as acute myeloid leukemia. The serine/threonine kinase, NEK1, is one of the 
eleven members of the NIMA-related kinases or NEK-family, which are important during mitosis. NEK1 is 
involved in sensing and repairing DNA strand breaks at the G1-S1 and G2-M transition191. RASA1 is a 
repressor of the RAS pathway and controls in that way cell proliferation. NCOA5 is a nuclear receptor  
co-regulator with activating and repressive function. The protein is described as a tumor suppressor in 
hepatocellular carcinoma in type II diabetes192. The anchoring protein, AKAP8, is responsible for the PKA 
compartmentalization and is in that way important during cell cycle193. INPP5D is a member of the inositol 
polyphosphate-5-phosphatase (INPP5) family. After phosphorylation it translocates from the cytosol to the 
membrane where it negatively regulates the PI3K pathway, and so proliferation, through hydrolysis of 
phosphatidylinositol-3,4,5-trisphosphate to phosphatidylinositol-1,3,4,5-tetrakisphosphate194. ANKS1 is a 
negative regulator of growth factor signaling by degradation of growth receptors through endocytosis195. 
 
In a fourth group we divided proteins known to be involved in cell adhesion and migration. The adaptor 
protein NCKIPSD stimulates WASP induced ARP2/3 complex formation and influences in that way the actin 
polymerization and so cell adhesion196. ARHGAP30 is a RhoGTPase activating protein involved in cell 
adhesion and migration197. Overexpression of the transcriptional regulator HNRNPAB results in an increased 
expression of SNAI1 and so in an increase in cell invasion198. The RAS repressor, RSU1, inhibits the 
PINCH1-ILK complex, which is involved in cell migration and upregulated in some tumors199. The 
tumorsuppressor LIMD1 is a transcriptional regulator that inhibits E2F transcription through interaction with 
retinoblastoma. Decrease of the expression of E2F target genes results in a reduced cell migration and 
proliferation200. PPP1R12A, is one of the subunits of the myosin phosphatases and is involved in cell division 
and migration through its regulation of the myosine phosphatase activity201. The atypical kinase PEAK1 (also 
named SGK269) is described to play a role in cell invasion and migration in breast cancer through changing 
phosphorylation of cytoskeleton-associated proteins MAPK1/ERK and paxillin202. 
 
The fifth group “Others” contains the phospho-proteomics results that could not be classified directly in the 
four other groups. This group contains the SNW1, RAVER1 and PPIL1 proteins involved in mRNA splicing 
and the RBM12B protein with a RNA binding motif of which the function is not yet clear203,204. RINL is 
involved in intracellular membrane trafficking by regulating endocytosis205. The RhoGTPase activating 
protein, ARHGAP27 (also named SH3D20), plays a role in clathrin-mediated endocytosis. SGK223 (also 
named D8ERTD82E) is involved in the regulation of neurite outgrowth206. HGS recycles and degrades 
receptors by lysosome-dependent degradation207. The PIK3AP1 and SKAP2 proteins are part of the B-cell 
receptor signaling in B-cells185,208. 
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Since we aimed to identify the signaling pathways contributing to the pathogenesis of T-ALL, we are 
interested in the group of proteins involved in proliferation, survival and migration. In particular, we focused 
on the tyrosine kinase PTK2B, because it is a known downstream signaling protein of the IL-2 and IL-7 
receptors and which is involved in cell proliferation and migration dependent on the cellular context. Atak 
et.al identified PTK2B as one of the new candidate driver genes in T-ALL after analysis of RNA-seq data in 
T-ALL samples177. Our goal was to identify the biological role of PTK2B in the development of T-ALL. We 
used the MOHITO cell line as model for our study because of its T-ALL characteristics, such as having 
Notch1 and Jak1 mutations, their dependency on IL-2 and IL-7 and the Jak/Stat pathway as the driving force 
for their proliferation. We confirmed the induction of rapid phosphorylation of Ptk2b after stimulation of 
MOHITO cells with IL-2 and IL-7. The activation of Ptk2b was completely dependent on the Src kinases and 
was negatively regulated by Ptpn2. Although Benbernou et al. described a block of proliferation in the IL-7 
dependent murine thymocyte cell line, D1, after targeting Ptk2b with an antisense oligonucleotides, we could 
not confirm that Ptk2b was involved in the cell proliferation of our T-cell leukemic cell line175. Neither  
siRNA-mediated downregulation of Ptk2b nor inactivation of Ptk2b using SRC inhibitors had an effect on the 
cell proliferation of the MOHITO cells. Since Ptk2b had no influence on the cell proliferation of the MOHITO 
cells, we investigated its role in the cell migration of these cells209. However, inactivation of Ptk2b by SRC 
inhibitors showed no difference in migration compared to control. Probably PTK2B is more involved in 
migration downstream of the TCR as described before170,172. Our functional data indicates that PTK2B is not 
an important driving force in the development of T-ALL.  
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CHAPTER V – GENERAL DISCUSSION 
 
Eukaryotic cells use protein tyrosine phosphorylation as a mechanism (i) to regulate signal transduction 
pathways, (ii) to communicate with neighboring cells and (iii) to transfer intracellular signals to induce a 
cellular response after an initial stimulus. The regulation of protein tyrosine phosphorylation is under tight 
control of PTKs and PTPs whereby PTKs phosphorylate proteins on tyrosine residues and PTPs counteract 
this action by removing the phosphate group. In general PTKs activate signaling pathways whilst PTPs are 
responsible for their inactivation, although exceptions to this rule are known to exist. This makes the PTKs 
and PTPs important regulators of cellular responses such as proliferation, survival, differentiation, metabolic 
regulation, motility, adhesion and migration. Not surprisingly, interruption of this tightly regulated balance 
between PTKs and PTPs contributes to the development of human diseases, including cancer. Genetic and 
epigenetic alterations affecting the PTK and PTP genes often account for the underlying cause of this protein 
tyrosine phosphorylation imbalance. These alterations can alter the enzyme activity, the subcellular 
localization or the expression levels of the PTKs and PTPs with severe consequences for the cell.  
 
Over the past few decades the role of PTKs in the development of cancer has been studied intensively. 
Although the PTKs form a small subgroup with 90 members out of the 518 proteins belonging to the protein 
kinase superfamily, this subgroup is more frequently mutated in cancer. This underlines again the 
importance of PTKs in the regulation of cellular functions. Numerous research studies investigating the 
mechanisms of oncogenic PTKs in cancer has also revealed insights into how PTKs are regulated and in 
which signaling pathways they are involved. This knowledge led to the development of promising PTK 
inhibitors with a higher specificity and less toxicity compared with many current chemotherapeutic agents. 
 
In the cancer research the use of cultured cancer cell lines have become useful models to perform 
experimental studies when there is restricted availability and limited supply of primary patient samples. 
These cancer cell lines are used to characterize the genetic background of the cancer from which they 
originate, to study signaling pathways involved in the tumor development, to perform RNAi and drug screens 
and to set up drug-resistant profiles. Although these cell culture lines are useful model systems, it is 
important to bear in mind they have some shortcomings. Cell culture lines are having genome instability and 
their long-term culture results in newly acquired genetic alterations to increase the genomic complexity as 
well as selection of a clonal tumor subpopulation. Cultured cancer cell lines also lack their natural 
microenvironment, which can have an influence on their behavior. Therefore, it is important that any findings 
found in cell culture lines are also confirmed with relevant primary cancer samples.  
 
Our laboratory has experience in using cytokine-dependent leukemic mouse cell lines for transformation 
studies and drug screens. In the lab, our cell line models of choice are the murine IL-3 dependent pro-B-cell 
line Ba/F3 and the IL-2 and IL-7 dependent T-cell line MOHITO. Overexpression of a mutant PTK with 
constitutive enzymatic activity will drive the proliferation of the cells independently of the cytokine signaling 
pathway. This makes the cytokine-dependent leukemic cell lines an interesting model to study the 
transforming capacity of newly identified PTK mutants, but also to test the sensitivity and specificity of newly 
developed compounds directed against the oncogenic PTKs. Treating the cells with drug compounds 
targeting the oncogenic PTKs will result in a reduction of the cell growth in the absence of the cytokine.  
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We used the transforming capacity of oncogenic tyrosine kinases in the IL-3 dependent cell line Ba/F3 to 
develop an RNAi screening system in selecting effective shRNA and siRNA molecules. RNAi is a process of 
gene silencing, whereby short RNA molecules target the mRNA in a sequence-specific manner for 
degradation. The synthesized RNAi molecules, shRNA and siRNAs, are used in the research to 
experimentally knockdown the expression of genes in cell lines or in cells in vivo and became interesting 
tools in therapeutic approaches. Besides difficulties with delivery and specificity, another major challenge of 
using RNAi molecules is selecting effective shRNAs or siRNAs that sufficiently downregulate the expression 
of the target gene. Although algorithms to design RNAi molecules have been improved lately, validation is 
still required before using them in experimental and therapeutic approaches. To this end, we developed a 
simple cell-based system in which the effect on proliferation of the Ba/F3 cells is used as  
read-out to select effective RNAi molecules. Specifically, our model Ba/F3 cell system overexpress a 
truncated form of PDGFRα, which drives their proliferation in the absence of IL-3. The transcript of the 
truncated PDGFRα is linked to a gene of interest. Introduction of shRNAs and siRNAs that effectively target 
the gene of interest will also lead to the degradation of the mutant PDGFRα transcript, which is detectable 
because of the block in cell growth. The cell proliferation as a primary end point read-out has an important 
advantage, since it is hard to predict in advance which reduction in protein level is required to have a cellular 
response. Furthermore, the Ba/F3 cells also have a rapid doubling time and can be transfected and 
transduced efficiently. Toxic effects caused by the RNAi molecules can be easily detected by rescuing the 
proliferation block through the addition of the growth factor IL-3. Another advantage, compared to other RNAi 
screens, is the independency in obtaining high transduction efficiencies. The shRNA constructs contain a 
GFP marker gene, which makes it possible to follow the cell proliferation according to the percentage of GFP 
positive cells.  
 
It was initially believed that PTPs were just housekeeping genes, which simply balance the effects of the 
PTKs. Recent functional studies and genetic screens indicate that PTPs are active regulators, which 
contribute in addition to PTKs, to the development of several cancer types. However, compared to the PTK 
research, studies of PTPs are lagging behind and many questions remain concerning their regulation, 
biological function and mechanism. The aim of the second part of my thesis was to study the role of PTPRD 
as a candidate tumor suppressor in the development of cancer, because gene inactivation through 
mutations, deletions and promoter methylations was frequently reported in different solid tumors66,68-70,103. 
Also our CNV analysis revealed a high frequency of PTPRD deletion in T-ALL and B-ALL samples. The 
PTPRD gene is located on the short arm of chromosome 9 in close proximity to CDKN2A, which is a  
well-documented tumor suppressor frequently lost in tumors. The short arm of chromosome 9 is often 
subjected to loss-of-heterozygosity in cancer, which could only be partially explained by loss of CDKN2A 
locus. Therefore, researchers postulated the existence of a second tumor suppressor gene on 9p69,70,210. 
Because of the high frequency of PTPRD inactivation in many cancers, PTPRD appeared to be a good 
candidate to fulfill the role as this second tumor suppressor next to CDKN2A. Veeriah et al. showed that loss 
of PTPRD is not driven by CDKN2A loss because different mechanisms, such as methylation and CNV, were 
responsible for the inactivation of these two loci70. Instead, we observed a simultaneous loss of PTPRD and 
CDKN2A due to deletions of larger parts of 9p in almost all of the ALL samples. This questions the tumor 
suppressive role of PTPRD in ALL, especially because we did not observe a correlation between the PTPRD 
gene expression levels and its CNV in the B-ALL samples.  
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Another observation is the loss of only one copy of PTPRD in all our analyzed ALL samples. Unlike 
CDKN2A, which is most common inactivated by one large deletion and one focal deletion or mutation of the 
second allele, PTPRD seems not to be homozygously inactivated. From our mutation analysis we can 
conclude that point mutations are not contributing to the inactivation of PTPRD, since the frequency is 
extremely low. However, it is still possible that PTPRD acts as a haploinsufficient tumor suppressor. The 
concept of haploinsufficiency is in sharp contrast with the two-hit hypothesis since it premises that even 
partial loss of a tumor suppressor gene is sufficient to contribute in tumorigenesis. Haploinsufficiency has 
already been shown previously for the tumor suppressor genes PTEN and TP53, whereby the function of the 
gene is coupled to the change in its expression level or protein activity166. Recently, Ortiz et al. observed that 
haploinsufficiency of the Ptprd gene promoted tumor progression in their GBM mouse model in cooperation 
with Cdkn2a deletions. Most GBM samples had focal deletions of the PTPRD locus in co-occurrence with 
focal deletions of the CDKN2A gene. In 87% of the samples with PTPRD deletions only one copy was lost. 
Heterozygous loss of Ptprd together with homozygous deletion of Cdkn2a in the GBM mice was more 
efficient in promoting tumorigenesis compared to wild type Ptprd and homozygous loss of Ptprd. This 
heterozygous loss of Ptprd concurrent with Cdkn2a loss was accompanied with an increase in pStat3. 
Although Stat3 is an important transcription factor in many proliferation pathways and previous functional 
data found Ptprd to be a growth inhibitor, the tumor progression in these mice was not caused by increased 
cell proliferation. Instead, Ptprd+/-p16-/- had enrichment in pathways involved in immune response and 
macrophage behavior113. Genetic analysis only in human cancer samples is not enough to define the 
haploinsufficiency of a tumor suppressor gene. Therefore, more in vitro and in vivo experiments are required 
to define the haploinsufficiency of PTPRD in other cancer types. Even though the role of PTPRD as a 
potential tumor suppressor in ALL is inconclusive, the extramedullary hematopoiesis observed in the Ptprd 
knockout mice and the PTPRD expression in human hematopoietic stem cells and progenitor cells suggest a 
potential role of PTPRD in hematopoiesis. More research is needed to define whether the extramedullary 
hematopoiesis is caused by defects in hematopoietic cells or in tissue cells of spleen or bone marrow. 
Understanding the biological role of PTPRD in hematopoiesis could help to gain more insights in its possible 
role in hematological malignancies. 
 
To determine whether our observations in ALL also correlate with solid cancers where PTPRD has already 
been shown to be a tumor suppressor, we extended our studies into melanoma. According to our results, the 
tumor suppressive role of PTPRD in melanoma is also questionable despite of the high mutation rate. 
Indeed, we observed a very low expression level of PTPRD in human and murine melanoma samples as 
well as in their normal cells of origin, the melanocytes. Moreover, the described mutations of the PTPRD 
locus seem to be introduced at a random basis, with mutations scattered the entire length of the gene and 
with a higher frequency in the introns than in the exons. As such, we hypothesize that the majority, if not all, 
mutations are passenger mutations, most likely introduced by UV radiation evidenced by the high frequency 
of C to T transitions. This hypothesis questioning the role of PTPRD as a bona fide tumor suppressor has 
also been brought into question by Clark et al. in neuroblastoma due to the very low PTPRD expression both 
in the neuroblastoma cells and the mouse embryo adrenal glands, the cells of origin of neuroblastoma. They 
could also not confirm a growth inhibition after reconstitution of PTPRD in neuroblastoma cell lines158. 
Although Solomon et al. have shown that PTPRD is involved in growth reduction after reconstitution of 
PTPRD in melanoma and GBM cells, these results are not indicative for the same biological function of the 
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endogenous protein in these cancer cells69. The same conclusion can be made for the STAT substrates of 
PTPRD, so far only identified in 293T cells. The 293T cell line is not a representative model for the cancers, 
and therefore STAT1 and STAT3 still need to be confirmed as substrates of PTPRD in the cancer cells.  
 
Last years with the increasing use of high-throughput screening methods, genetic data are produced in 
massive amount, which results in the discovery of many novel genetic alterations in different cancer types. In 
that way genetic alterations in PTPRD were observed in many different cancer types. However, the 
occurrence of mutations in specific genes is not sufficient to establish their role as tumor suppressor genes, 
and our data strongly suggest that PTPRD is not relevant in melanoma development. Loss of PTPRD may 
contribute to the development of other cancers, and it will be of interest to study a possible tumor 
suppressive role of PTPRD in lung, colorectal and head and neck cancer, since PTPRD deletions and 
promoter methylations were found in these cancer types. In a first step the expression levels of PTPRD in 
the healthy tissues and the cancer samples should be defined. When the phosphatase is expressed in the 
healthy tissues and the expression levels in the cancer samples correlates with the genetic data, the 
biological function of PTPRD should be further investigated in cancer cell lines. Its role in cell proliferation 
could be studied by performing proliferation and apoptosis assays in cancer cell lines after RNAi-mediated 
knockdown. It would be interesting to investigate whether STAT1 and STAT3 are downstream signaling 
proteins in these cancer cell lines. Phospho-proteomics is a useful technique to identify other signaling 
pathways controlled by PTPRD, which would contribute to the understanding of the biological role of PTPRD 
in these cancer types. As shown by Ortiz et al. in GBM, a possible cooperation of loss of CDKN2A and 
PTPRD should be studies as well in other cancers with high frequencies of deletions of these loci. From this 
part of the thesis, we can underline the importance of performing gene expression analysis and functional 
studies in cell lines as well as in mouse model and patient samples, in addition to the genetic analysis of the 
cancer samples. 
 
In the last part of my thesis, we used phospho-proteomics to identify other signaling pathways controlled by 
PTPN2 in leukemic cells. Previously, the JAK/STAT and NUP214-ABL1 proliferation pathways are described 
to be negatively regulated by this non-receptor protein tyrosine phosphatase in T-ALL. However, other 
signaling pathways involved in T-ALL and under control of PTPN2 remained unknown. Phospho-proteomics 
is an interesting high-throughput screening system to study the difference in protein tyrosine phosphorylation 
between cell lines with and without a PTP. Analysis of our phospho-proteomics data identified 38 proteins 
with a higher phosphorylation level on their Tyr residue in the leukemic T-cell line, MOHITO, with knockdown 
of PTPN2 compared to control. The identification of signaling proteins involved in T-cell signaling and 
immunologic synapses confirmed the role of PTPN2 in immune response and auto-immune diseases. Also 
many signaling proteins involved in cell proliferation and migration are under control of PTPN2, including 
PTK2B, which we studied in more detail. Although Ptk2b functions downstream of IL-7R pathway, which 
drives the proliferation in MOHITO cells, Ptk2b was not involved in the cell proliferation or migration of these 
cells. Interestingly, PTK2B also functions downstream of the TCR, where it modulates the actin cytoskeleton. 
In T-cells, the IL-7R pathway maintains their homeostasis, whereas the TCR signaling pathway induces an 
immune response after antigen-induced stimulation. During this TCR signaling, the IL-7R pathway is 
inhibited by a change in the balance of pro- and anti-apoptotic proteins. However, the exact mechanism 
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behind this switch in signaling proteins is unknown. PTK2B might be involved in this crosstalk between these 
pathways211,212.  
 
Although we could not provide evidence that PTK2B is contributing to the pathogenesis of T-ALL, the 
phospho-proteomics identified several other proteins downstream of PTPN2 that might be involved in the 
development of T-ALL. The KIT tyrosine kinase, for example, appeared also in the phospho-proteomics data 
and has a known role in cell proliferation. The KIT protein is a proto-oncogene in acute myeloid leukemia, but 
is also expressed in some T-ALL patient samples. Therefore, researchers have described KIT as a candidate 
oncogene in T-ALL, although its transforming capacity in this malignancy has not been investigated in great 
detail213-215. For the other identified proteins involved in cell proliferation (CBL, NEK1, RASA1, NCOA5, 
AKAP8, INPP5D and ANKS1) there were no genetic analyses or functional data published that indicate their 
potential role in the pathogenesis of T-ALL. It would be of interest to perform genetic analyses of T-ALL 
datasets to define the presence of genetic alterations in these genes. The phospho-proteomics revealed also 
many proteins involved in T-cell signaling and formation of immunological synapses. Investigating the role of 
PTPN2 in these signaling pathways could contribute to our understanding of the role of PTPN2 in the 
pathogenesis of autoimmune diseases. 
 
The question remains why PTP research is still lagging behind that of PTKs. One reason may be that the 
active role of PTPs in regulating the tyrosine phosphorylation was long underestimated. PTPs were long 
seen as housekeeping enzymes maintaining the basal level of tyrosine phosphorylation. Recently, genetic 
analyses revealed more and more gene alterations of PTPs in cancer samples, indicating their active 
contribution in the carcinogenesis. Functional studies of the oncogenic capacity of PTKs are mostly more 
straightforward since activating mutations or PTK overexpression results in an obvious difference in, for 
example, cell proliferation. Loss of tumor suppressive PTPs require in most cases at least two hits for 
complete inactivation, which complicates and extends the genetic analyses. In case of haploinsuffiency, it is 
even hard to define which level of protein reduction is causing the phenotype. Moreover, very often loss of a 
PTP is compensated by other PTPs. For example the PTPRD family members LAR and PTPRS can 
compensate for its loss in neuronal biology87,98. Furthermore a PTP can have more than one function 
depending on the cellular context. In T-cells, PTPN2 is involved in controlling the immune response as well 
as their cell proliferation by regulating different signaling pathways. More striking, the same PTP can act 
either as an oncogene or a tumor suppressor depending on the malignancy. Again the example of PTPN2, 
which loss through deletions contributes to the development of T-ALL due to increased activation of the 
JAK/STAT pathway43,44. In contrast, elevated levels of PTPN2 were observed in activated B-cell-like diffuse 
large B-cell lymphoma. The elevated expression of PTPN2 was associated with a tumor-promoting effect 
through indirect inhibition of IL-4 mediated cell cycle arrest caused by dephosphorylation of STAT6216. The 
fact that not a lot of PTP ligands and substrates are identified is also impeding this research in understanding 
the biological role of PTP and their contribution to the development of human diseases, such as cancer. 
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